Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2021

Multimorbidity, Healthcare Processes, and Mortality Among TB/
HIV Patients Treated With Antiretroviral Therapy in Uganda
Abel Nkolo
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an
authorized administrator of ScholarWorks. For more information, please contact ScholarWorks@waldenu.edu.

Walden University
College of Health Professions

This is to certify that the doctoral dissertation by

Abel Nkolo

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. German Gonzalez, Committee Chairperson, Public Health Faculty
Dr. Tina Cunningham, Committee Member, Public Health Faculty
Dr. Simone Salandy, University Reviewer, Public Health Faculty

Chief Academic Officer and Provost
Sue Subocz, Ph.D.

Walden University
2021

Abstract
Multimorbidity, Healthcare Processes, and Mortality Among TB/HIV Patients Treated
With Antiretroviral Therapy in Uganda
by
Abel Nkolo

MPH, Makerere University, 2009
MBChB, Mbarara University of Science and Technology, 2000

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health

Walden University
February 2021

Abstract
Globally, Uganda is one of the 30 tuberculosis (TB) and human immunodeficiency virus
(HIV) high burden countries with high antiretroviral therapy (ART) coverage, yet
mortality is still high among TB/HIV patients on ART. The reasons for the high mortality
have not been fully explored. The purpose of this study was to determine the association
between multimorbidity, age, sex, marital status, phase of TB treatment, timing of
initiation for ART, and type of TB and mortality among TB/HIV patients on ART in
Uganda. The health outcomes conceptual framework with 3 domains that directly or
indirectly affect the outcome domain was used to guide the study. A quantitative crosssectional study design was used. The target population of 3,850 deidentified TB/HIV
patients on ART, and data were abstracted from 2017, 2018, and 2019 medical records in
9 out of 14 systematically selected regional hospitals in Uganda. Descriptive analysis and
binary logistics regression were conducted. TB/HIV patients on ART with 1 or 2 or more
multimorbidity were 1.658 times and 1.901 times more likely to die than patients with no
multimorbidity. TB/HIV patients on ART who were separated/divorced or single were
1.591 and 1.381 times more likely to die than married patients. The TB/HIV patients on
ART who began ART treatment after TB treatment were 1.899 times more likely to die
than patients who started ART before TB. The results can support social change by
raising awareness among policymakers, national TB program staff, and health workers to
implement approaches like patient-family-centered care to prevent deaths among TB/HIV
patients on ART.
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Chapter 1: Introduction to the Study
Introduction
Antiretroviral therapy (ART) improves tuberculosis (TB) treatment outcomes
among patients with TB disease who are coinfected with human immunodeficiency virus
(HIV). According to Engelbrecht et al. (2017), successful TB treatment outcomes in
TB/HIV coinfected patients happens in those with high cluster of differentiation 4 (CD4)
cell count (greater than 350) on cotrimoxazole and ART (Engelbrecht et al., 2017).
Weldegebreal et al. (2018), in a study conducted in Ethiopia, noted that patients below 18
years of age with extrapulmonary TB and on ART had improved TB outcomes. However,
Weldegebreal et al. (2018) also noted that the treatment outcomes were not as high as
recommended by the World Health Organization (WHO, 2018) at 90%. According to
WHO (2018), 21 out of 27 high TB/HIV burden countries reported treatment outcomes
below 85%, yet the global standard is 90%. Poor treatment outcomes include mortality,
loss to follow up, failure, transfer out, and not evaluated. Mortality and loss to follow up
constitute the poorest treatment outcomes among TB/HIV patients, with a mortality of
9% in the Africa region. Although ART improves TB treatment outcomes among
TB/HIV patients on ART, mortality remains high, especially in high burden TB/HIV
countries.
According to WHO (2018), in Uganda, mortality among TB/HIV patients is
32/100,000, which is higher than 26/100,000 among TB patients who are HIV negative.
High mortality among TB/HIV patients is attributed to several factors, such as delayed
testing for TB, delayed start on ART, and anti-TB medicines (WHO, 2018). Furthermore,
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Worku et al. (2018) noted that other common opportunistic infections that are not
diagnosed may lead to mortality in TB/HIV patients. Generally, multimorbidity is
associated with mortality (Academy of Medical Sciences [AMS], 2018; Oni et al., 2015;
Smith et al., 2018). However, based on the literature, it is not clear whether
multimorbidity, other patient characteristics, and health care processes are associated
with mortality among TB/HIV coinfected patients on ART (AMS, 2018; Oni et al., 2015;
Smith et al., 2018). There is a need to explore further why mortality remains high among
TB/HIV patients on ART. In this study, based in Uganda, I explored the association of
multimorbidity and health care processes with mortality among TB/HIV coinfected
patients on ART.
The study results could reveal new knowledge of multimorbidity and mortality
among TB/HIV patients on ART, which would impact positive social change. Health
workers might use this new knowledge to help make decisions on TB/HIV coinfected
patients with multimorbidity to avoid mortality. The resulting data could be used in
designing policies and guidelines on multimorbidity in Uganda. In Chapter 1, I describe
the study’s background, problem statement, purpose of the study, research questions, and
hypotheses. I also describe the conceptual framework, definitions, nature of the study,
assumptions, scope and delimitations, limitations, the significance of the study to theory,
practice, and social change. I conclude this chapter with a summary and transition.
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Background of the Study
TB/HIV Coinfection
Globally, TB/HIV remains a public health problem, especially in sub-Saharan
Africa. WHO listed 30 TB/HIV burden countries, 23 out of 30 countries are found in subSaharan Africa, including Uganda (WHO, 2018). In 2005, WHO recommended 12
TB/HIV collaborative activities, which have been adopted by countries. These broadly
include setting up mechanisms for TB/HIV collaboration, reducing the burden of TB in
HIV patients, and reducing the burden of HIV in TB patients (WHO, 2015).
Additional activities include implementing TB/HIV integrated services using
either a one-stop shop, partially integrating services, colocating services with referral
between the HIV and TB clinics or referring TB/HV patients between TB and HIV health
facilities (WHO, 2015). The integration ensures that TB/HIV patients are managed
holistically (WHO, 2018). Although WHO has made recommendations to deal with the
persistent global problem of TB/HIV, mortality among TB/HIV patients still needs more
attention.
Mortality in TB/HIV Coinfected Patients on ART
It is well known that mortality is reduced in TB/HIV patients when they start
ART early. Nagu et al. (2017) indicated that well-planned and highly supervised ART
reduces mortality in TB/HIV patients and that death occurs early during TB treatment.
According to Engelbrecht et al. (2017), in a retrospective study conducted in South
Africa, successful TB treatment outcomes in TB/HIV coinfected patients happens in
those with high CD4 cell count (greater than 350), on cotrimoxazole and ART. If well-
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supervised, ART administered early in TB/HIV patients reduces mortality among
TB/HIV patients. Bruchfeld et al. (2015) highlighted that HIV comorbidities may be
responsible for mortality among TB/HIV patients who develop immune reconstitution
inflammatory syndrome (IRIS). TB IRIS is one paradoxical phenomenon that must be
dealt with when TB/HIV coinfected patients start either ART or anti-TB medicines
because it leads to patient deaths.
Uganda started the test and treat policy in 2013, focusing on initiating ART within
4 weeks of starting anti-TB treatment for TB/HIV patients. The ART coverage among TB
patients reached 90% in 2016 and is 98% in 2018 (Ministry of Health, Uganda [MoH],
2018). However, the mortality in TB/HIV patients is still high at 12% based on data from
MoH (2018), and 15.5% based on research by the Makerere School of Public Health
(2018). Even in Uganda, the reasons for high mortality are unknown, although some
researchers have pointed out delayed testing for TB, delayed start on ART, and anti-TB
medicines (WHO, 2018). For Uganda, mortality among TB/HIV patients on ART is still
high, yet the reasons for the high mortality are not well known.
Prevalence and Patterns of Multimorbidity Among TB/HIV Patients on ART
Studies in South Africa have demonstrated a pattern of common comorbidities,
including infectious diseases and non communicable diseases. The observed diseases
include hypertension, diabetes, HIV, and TB. Oni et al. (2015), in peri-urban South
Africa, studied the epidemiology of HIV, TB, and non communicable diseases
multimorbidity and found that HIV, TB, diabetes mellitus, and hypertension accounted
for 45% of prescription visits, thus reflecting the magnitude of multimorbidity. Pepper et
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al. (2015) found similar results in a study conducted in Khayelitsha, South Africa,
indicating that TB patients have a comorbidity of about 37% of hypertension and 12% for
diabetes mellitus. Hypertension and diabetes mellitus were more prevalent among
younger patients on ART than those not on ART.
Epidemiological transition in developing countries is characterized by a double
burden of infectious and non infectious diseases. The issue of multimorbidity in this
study aligned with the epidemiological transition in developing countries (Oni et al.,
2015). Other comorbidities have been noted in TB and HIV patients, including cancers,
malaria, pneumonia, malnutrition, and smoking (Marais et al., 2013). The standard
patterns for TB/HIV comorbidities were TB/HIV hypertension and TB/HIV diabetes
mellitus. The epidemiological transition may explain the double burden of infectious and
communicable diseases from infectious to chronic disease (Oni et al., 2015). Comorbidity
was known to be lower in TB/HIV patients on ART rather than those not on ART, but
higher in the young age ranges of 18–35 years and 36–45 years (Oni et al., 2015). Oni et
al. further highlighted the need for research for comorbidities among TB/HIV patients.
Although the patterns of infectious and noninfectious diseases have been explored in
South Africa, the patterns of multimorbidity among TB/HIV patients still need to be
explored beyond South African studies.
Assessment of Comorbidities/Multimorbidity
Tools to measure comorbidities/multimorbidity have been developed focusing on
non communicable diseases. These tools have been used to study the magnitude of
comorbidities as an indication of the quality of life of patients, especially in developed
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countries inpatients and patients over 65 years of age (Brown et al., 2015). These tools
have been improved further to include non communicable diseases like HIV and TB
(Brown et al., 2015). The tools have evolved, and now there is a functional assessment of
chronic illness therapy–tuberculosis (FACIT) tool, which is a TB-specific tool to measure
comorbidities and the quality of life among patients with TB (Dujaili et al., 2015).
The health status of an individual can be assessed by counting multimorbidities.
The number of comorbidities in an individual is associated with the likelihood of that
individual’s death (Brown et al., 2015). The score of the count of diseases is called the
comorbidity index. There are several comorbidity indices: Charlson comorbidity index,
RX Risk comorbidity assessment, Elixhauser comorbidity Index, and Johns–Hopkins
adjusted clinical group. The Charlson comorbidity index is the most common tool used to
measure comorbidity. The tool is based on a list of 17 elements with each condition
assigned a weight of 1 to 6, with a 0 indicating no comorbidity (Lix et al., 2016; Wallace
et al., 2016).
Effects of Multimorbidity on Mortality
Although the effects of multimorbidity on mortality have been studied, mortality
among TB/HIV patients with multimorbidity has not been well described (Samuels et al.,
2018). The effects of multimorbidity on health care are varied. According to Oni et al.
(2015), the effects include failure for the patient to manage themselves because of many
diseases, the need for the health care provider to have multiple skills to deal with many
diseases, the need for several requirements, equipment, design, and infrastructure of the
health system.. The findings indicate that the effects of multimorbidity are at different
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levels, including patient level, health system level, and provider level, which all need
special attention.
Mortality is a core outcome of multimorbidity. However, the association between
multimorbidity and mortality among TB/HIV patients on ART has not been well
established. Globally, there is an ongoing debate on multimorbidity and the lacking
research in all areas, especially from low-middle-income countries (Catala-Lopez, et al.,
2018; Xu et al., 2017). Studies in sub-Saharan Africa have indicated a rise in
multimorbidity patterns and the overlap between infectious diseases and non
communicable diseases, including, hypertension, diabetes mellitus, cancers, and others
(Oni et al., 2015). In Uganda, the mortality in TB/HIV patients is high at 12%, despite the
implementation of an HIV test-and-treat policy with ART coverage among TB/HIV
patients at 98% (MoH, 2018; WHO, 2018). Understanding the relationship between
multimorbidity, health care processes, and mortality among TB/HIV patients is crucial in
addressing the high mortality among this population. I explored and tested the association
between multimorbidity, health care processes, and mortality among TB/HIV coinfected
patients on ART in Uganda. The information could contribute to the ongoing debate of
multimorbidity health care processes and their influence on mortality among TB/HIV
patients on ART. Health workers could use the information to make appropriate decisions
on how to handle TB/HIV patients. Policymakers and managers could further use the
results to contribute to developing policies for patients with comorbidities.
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Problem Statement
There is high mortality among TB/HIV coinfected patients on ART in Uganda
despite high ART coverage. According to MoH, the mortality in TB/HIV patients was
11–12% from 2014 to 2017, despite ART coverage of 60–98% (MoH, 2018; WHO,
2018). The reasons for the high mortality have not been explained but have been
associated with a delay in the start of ART, delay in testing TB patients for HIV, and
IRIS (WHO, 2018). High mortality among TB/HIV patients is still a challenge at the
global level. According to WHO (2018), mortality among TB/HIV patients is 11%. In
sub-Saharan Africa, mortality in TB/HIV patients is 9%, whereas in Uganda, it is 12%
(WHO, 2018). According to Mchunu et al. (2016), Swaziland has recorded high mortality
among TB/HIV patients at 14%. The reasons for mortality are not well understood, but
the issues explained relate to failure to decentralize treatment from doctors to nurses
(Mchunu et al., 2016).
Global studies have indicated that multimorbidity is an increasing concern and is
associated with low quality of care and death. In sub-Saharan Africa, multimorbidity is
increasing, as seen from studies conducted in South Africa (Oni et al., 2015). The
existing studies on mortality and TB/HIV coinfected populations on ART have indicated
inadequate information on the association of multimorbidity and mortality among
TB/HIV coinfected patients on ART (Mchunu et al., 2016; Oni et al., 2015; Pepper et al.,
2015). There is inadequate information about multimorbidity in middle-income and
lower-income countries, including Uganda (Catala-Lopez et al., 2018). Mortality is a
known core outcome of multimorbidity. The need to study multimorbidity, health care
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processes, and their association to mortality in Uganda was paramount (Catala-Lopez et
al., 2018; Smith et al., 2018; Xu et al., 2017). The purpose of the study was to test and
analyze the association between multimorbidity, health care processes, and death among
TB/HIV patients on ART. The independent variables were multimorbidity, age, sex,
marital status, phase of TB treatment, time of initiation of ART, and type of TB. The
dependent variable was mortality.
Purpose of the Study
The purpose of this quantitative study was to test and analyze the association
between multimorbidity, health care processes, and mortality among TB/HIV patients
treated with ART in Uganda. The independent variables were multimorbidity, measured
as yes or no. Multimorbidity in this study meant patients with TB/HIV with two or more
diseases in addition to TB and HIV. Examples of these diseases are diabetes mellitus,
hypertension, malnutrition, pneumonia, and cancers. The other independent variables
were age, sex, marital status, the type of TB, phase of TB treatment, and initiation timing
for ART measured as yes or no. The dependent variable was mortality, measured as yes
or no.
Research Questions and Hypotheses
In this study, I addressed the following research questions with corresponding null
and alternative hypotheses:
RQ1: What is the association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART?
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H01: There is no association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART.
Ha1: There is an association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART
RQ2: What is the association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART?
H02: There is no association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
Ha2: There is an association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
RQ3: What is the association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART?
H03: There is no association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
Ha3: There is an association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
RQ4: What is the association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV
patients on ART?
H04: There is no association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
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Ha4: There is an association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
RQ5: What is the association between type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among
TB/HIV patients on ART?
H05: There is no association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Ha5: There is an association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Using binary logistics regression, I tested and analyzed the associations between
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, the timing of
initiation for ART, and mortality among TB/HIV patients on ART.
Conceptual Framework
The conceptual framework for this study was the health outcomes conceptual
framework. The health outcomes conceptual framework relates to a complex interplay
between a health system’s 4 domains, patient factors, care path, and health outcomes
(Canadian Institute for Health Information, 2008; Sbarigia et al., 2016). The health
outcomes framework has its origins in the Donabedian model used for quality of care
improvement developed in 1967 and implemented in the 1980s (1980, 1986, and 1988).
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The Donabedian model includes three levels: (a) the structure or context, which is the
setting for health care delivery; (b) the process where medical interventions are
implemented; and (c) the outcome, which is the impact of health outcomes (Canadian
Institute for Health Information 2008; Sbarigia et al., 2016). Apart from its use in quality
improvement, this framework has been used in the study of processes in health care
delivery settings and how the processes impact health outcomes.
The framework is also related to outcomes research studies in which researchers
focused on chronic issues like mental health and diabetes. The framework has also been
used in the Hepatitis C outcomes framework (Canadian Institute for Health Information
2008; Sbarigia et al., 2016). Based on its simplicity in studying patient-level outcomes,
the outcomes conceptual framework was used to explore the relations between patient
characteristics, multimorbidity, and mortality, contributing to patient-level outcomes.
Using this health outcome conceptual framework, I focused on testing and analyzing the
association of multimorbidity, age, sex, marital status, phase of TB treatment, time of
initiation on ART, and type of TB with mortality among TB/HIV coinfected patients on
ART in Uganda (Bates et al., 2015). The health outcomes framework was the most
appropriate framework to use because it can be used to explore the relation of mortality
and aspects of health structure, patient characteristics, and care process (Canadian
Institute for Health Information, 2008).
The critical elements of the framework are the structure or context (health care
system structure or context), patient factors, care path, and health outcomes (Canadian
Institute for Health Information, 2008; Sbarigia et al., 2016). The health care system
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structure is the mechanism patients obtain health care through. There are providers,
clinics, and records, so patient characteristics, provider characteristics, and surveillance
are necessary. Patient factors include social demographics (age, gender, ethnicity,
education, income, marital status, and socioeconomic attributes); risk factors like
smoking, drinking, physical activity and diet; and expectations or preferences of the
patient. The care path includes interventions. Interventions are what is given to the
patient to change the health care status, including prevention, treatment, and care. The
processes of care in this study were anti-TB medicines, ART, and cotrimoxazole
preventive therapy. The health outcomes were the status achieved after the
implementation of interventions. Health outcomes may be either patient-related outcomes
or health-system outcomes. Patient-related outcomes include health status, health-related
measures, and non-health-related measures. The following are examples of the healthrelated measures, quality-adjusted life years, disability-adjusted years, health-related
measures like hospital admissions, complications, or test results, whereas non-healthrelated measures include patient satisfaction. At the population level, health system
performance measures apply at the national level, and the health outcomes include
morbidity prevalence and mortality (Canadian Institute for Health Information, 2008;
Sbarigia et al., 2016). In this study, I focused on mortality, which is under patient-level
health outcomes (Brown et al., 2016).
The health outcomes conceptual framework provided a logical framework for
studying multimorbidity among TB/HIV patients on ART. The conceptual framework
also offered a line of thinking from the structure processes to outcomes, emphasizing
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what happens rather than what went wrong, as highlighted by Donabedian. That kind of
thinking is followed in the quality of care to improve patient health status and, therefore,
multimorbidity. Based on this framework, the health outcomes and the health-related
outcome (mortality) were the dependent variables. The other categories, like patient
characteristics, formed the outcome variable or independent variable (multimorbidity).
Several tools, like the Charlson comorbidity index tool and specific TB tools like the
FACIT TB tool, could be used to measure TB-related comorbidities (Dujaili et al., 2015;
Mamani et al., 2014). TB/HIV documents were reviewed to confirm the different patient
characteristics, including multimorbidity. The health outcomes conceptual framework
was used to guide the study on multimorbidity, healthcare processes versus mortality
among TB/HIV patients on ART in Uganda. The data analyzed were related to the flow
of the framework.
Nature of the Study
In this study, I used quantitative research methods with a cross-sectional design,
coupled with a retrospective review of medical records to retrieve secondary data
(Rudestam & Newton, 2015; van den Akker et al., 2001). Many studies have been
conducted on comorbidity and multimorbidity. Researchers have used cross-sectional
studies with a review of records (Oni et al., 2015; Peltzer, 2018; Pepper et al., 2015,
Weimann et al., 2016). Furthermore, Catala-Lopez et al. (2018) noted that in various
systematic studies researchers used a cross-sectional design to study multimorbidity in
different countries. Cross-sectional studies are being used in the description of variables,
description distribution of multimorbidity patterns, and examination of associations
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between predictors and outcomes (Hulley, 2007). Also, cross-sectional studies could be
used to provide information on those with a disease or a condition at a given point in time
(Hulley, 2007).
To ensure external validity, several issues that affect generalization, like selection
bias, were dealt with by ensuring a representative sample was selected from the regional
referral hospitals in Uganda that handle TB/HIV patients. The regional referral hospitals
in the sample were chosen systematically. All TB/HIV patients on ART were included in
the sample to make the minimum required sample for each facility. An adequate sample
was maintained by calculating the sample size required to ensure that the study has
adequate power (Rudestam & Newton, 2015). The data collected included
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, timing of
initiation for ART, and mortality data. The selected variables were based on findings
from other studies of comorbidities and multimorbidity in sub-Saharan Africa (Bates et
al., 2013; Creswell, 2011, Oni et al., 2015; Pepper et al., 2015).
After authorization by the Walden University Institutional Review Board (IRB; #
01-31-20-0226229), Makerere University Higher Degrees Research Ethical Committee
(#772), the Uganda National Council of Science and Technology (#HS692ES), the MoH,
and regional referral hospitals, the following were accessed for data abstraction: TB
registers, ART cards, patient files, and electronic registers. All patient data were
deidentified. I conducted quantitative binary regression to test the associations between
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, timing of
initiation for ART, and mortality among TB/HIV patients on ART in Uganda.
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Definitions
Antiretroviral therapy (ART): A combination of antiretroviral drugs that suppress
HIV and stop the progression of HIV disease (WHO, 2015).
Diabetes mellitus: Diabetes leads to raised blood sugar called hyperglycemia and
is a disease of chronic nature (WHO, 2015).
Health care system: A mechanism through which patients get health care from
health care providers (Canadian Institute for Health Information 2008; Sbarigia et al.,
2016).
Health outcomes: Changes in health that result from the implementation of
interventions. Health outcomes may be patient-related outcomes or health system
outcomes (Canadian Institute for Health Information 2008; Sbarigia et al., 2016).
Hypertension: A situation in which an individual has high or raised blood
pressure. Normal blood pressure is less than 120/80 mm Hg. Elevated blood pressure has
systolic readings between 120-129 and diastolic readings less than 80; Stage 1: Systolic
between 130-139 or diastolic between 80-89;while Stage 2: Systolic at least 140 or
diastolic at least 90 mm Hg; a hypertensive crisis: Systolic over 180 and/or diastolic over
120 (Carey & Whelton, 2018).
Multidrug-resistant TB (MDR-TB): TB resistant to at least rifampicin and
isoniazid, the two most effective anti-TB drugs (WHO, 2015).
Multimorbidity: Existence of more than one medical condition or situation in an
individual (AMS, 2018).
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Noncommunicable diseases: Noninfectious health conditions typically caused by
genetic, environmental, and lifestyle factors (Bates et al., 2015).
Patient factors: Characteristics that include social demographics (age, gender,
ethnicity, education, income, marital status and social, economic attributes); risk factors
like smoking, drinking, physical activity and diet; and expectations or preferences of the
patient (Sbarigia et al., 2016).
Process of care: Interventions, including prevention and care interventions
(Sbarigia et al., 2016).
TB/HIV coinfected patients: TB disease occurring in someone infected with HIV
(WHO, 2015).
Assumptions
The first assumption in this study was that all HIV patients are screened for TB,
and all those who had TB were diagnosed. This assumption was based on the WHO
recommendation that all HIV patients be screened for TB at every health facility visit.
Another assumption was that all multimorbidity in TB/HIV coinfected patients had been
recorded on the ART cards and that all records were as complete as possible. At
hospitals, there are dedicated records officers who fill in the information in the Unit TB
register and the ART cards. Based on ART clinic practice, the record details of any
multimorbidity and medications are recorded on the ART card. A third assumption was
that all TB/HIV patients are administered both anti-TB medicines and ART. This
assumption was based on the WHO recommendation adopted in 2013 in Uganda. All
TB/HIV patients should be started on anti-TB treatment immediately after diagnosis and
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ART within 2 months or as soon as they can tolerate ART and based on the recent testand-treat policy (WHO, 2016). However, it was beyond the scope of this study to prove
that all TB/HIV coinfected patients in the communities are diagnosed and administered
anti-TB treatment and ART.
Scope and Delimitations
The specific aspects of the research problem addressed in the study were related
to the selected patients’ characteristics. The characteristics included gender, age, type of
TB, multimorbidity (diabetes mellitus, hypertension, malnutrition, pneumonia, cancer),
and health care processes like phase of TB treatment and timing of initiation for ART
among TB/HIV patients on ART. Multimorbidity may be associated with mortality. The
multimorbidity, health care processes, and mortality among TB/HIV patients on ART
were studied to understand the relationship and support remedial actions.
The study participants included all TB/HIV patients on ART. The study excluded
all TB/HIV patients on ART who had missing outcome variables. I used the health
outcome conceptual framework for this study, a broad framework with some aspects not
included in the study. The framework has three levels, the structure or context
representing the health care delivery setup, the process representing how medical
interventions occur, and the health outcomes. However, in this study, only parts of the
three levels of the conceptual framework were studied. The parts of the conceptual
framework that were studied included patient characteristics, which is part of the context,
and mortality as the health outcome, the processes of the health outcomes, and mortality
as health outcomes. The outcomes framework is so broad that some parameters were not
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studied. Population-level outcomes, which include mortality rates and morbidity rates,
were not studied. Other elements not studied in the context included the provider
characteristics, the surveillance system, and clinic characteristics. This study is
generalized to a study population in Uganda of TB/HIV patients on ART, focusing on
multimorbidity and mortality.
Limitations
One of the critical limitations of this study was missing data or incomplete
records encountered during data retrieval. To ensure that this limitation was minimized,
patients were oversampled to cover for these data gaps. There could have been a threat of
statistical validity, in which the sample size is too small to show any effect (Harris,
2016). I calculated the sample size to overcome statistical threat validity due to the small
sample size. I ensured that more participants beyond the calculated sample were included
in the sample to cater for missing data. During analysis, this adequate sample was used to
make conclusions.
Significance of the Study
Significance to Theory
The types of multimorbidity among TB and HIV patients are known. However,
the multimorbidity and its association with mortality among TB/HIV coinfected patients
on ART have not been explicitly studied (AMS, 2018). The results of this study highlight
the associations between multimorbidity, health care processes, and TB mortality among
TB/HIV patients on ART in Uganda. The results of the study can contribute to new
knowledge regarding multimorbidity and mortality among TB/HIV patients on ART.
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Significance to Practice
Testing the associations between multimorbidity, health care processes, and
mortality has helped to highlight the critical multimorbidities associated with mortality.
In alignment with WHO’s strategy to end TB and the era of comorbidity, it is essential to
know and manage the multimorbidities appropriately for TB/HIV patients on ART
(WHO, 2016). Health providers could use this study’s results to understand common
multimorbidities among TB/HIV patients on ART. The results could also provide insights
to national TB program managers to plan appropriately (human resources, medicines,
infrastructure, training) in managing and following up TB/HIV patients with various
multimorbidities (WHO, 2016).
Significance to Social Change
Regarding positive social change, this study’s results could be disseminated to the
national TB program and organizations working in communities to plan, manage,
monitor, and improve the way multimorbidity is managed among TB/HIV individuals
and their families and the general community. Managers could use the results to improve
patient health, including networks of TB patients coinfected with TB and who have other
comorbidities. The results could also contribute to policies on multimorbidity because it
is a new area on the global scene and is likely to be recognized in developing countries.
Summary and Transition
In TB and HIV patients, multimorbidity is associated with poor health outcomes,
regardless of whether they are on ART. There is still inadequate information on the
prevalence and consequence of multimorbidity among TB/HIV coinfected patients
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initiated on ART (Mchunu et al., 2016; Pepper et al., 2015). The purpose of this study
was to test the association of multimorbidity, health care processes, and mortality among
TB/HIV patients on ART in Uganda. The independent variables were multimorbidity,
phase of TB treatment, initiation of ART after the start of TB treatment, and type of TB.
The dependent variable was mortality. I used a cross-sectional study design with
quantitative methods and secondary data review (Rudestam & Newton, 2015; van den
Akker et al., 2001). I analyzed and tested the association between mortality and
multimorbidity among TB/HIV patients on ART in Uganda. I analyzed the associations
between the independent variables and dependent variables using binary logistics
regression. I conducted a multivariate analysis using binary logistics regression (van den
Akker et al., 2001).
I am hopeful that managers, policymakers, and community organizations might
use the results of this study to improve practice in health facilities and communities.
Further, this study’s results are likely to impact social change so that patients and
networks with multimorbidity are managed by the health care system and in
communities. In Chapter 2, I expound on the sections covered in Chapter 1 by reviewing
the literature in detail to deepen the understanding about TB/HIV, exploring available
literature regarding the independent and dependent variables, conceptual framework, and
previous studies.
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Chapter 2: Literature Review
Introduction
Uganda is a high-burden country for TB/HIV and is among the 30 TB/HIV highburden countries with poor TB treatment outcomes. The country still records mortality of
about 13% among TB/HIV coinfected patients on ART, despite high ART coverage
(MoH, 2018; Musaazi et al., 2019; WHO, 2018). A further review of current studies
shows that mortality is a core outcome of multimorbidity. The studies also highlight the
inadequate literature on multimorbidity in middle- and low-income countries (CatalaLopez et al., 2018; Smith et al., 2018; Xu et al., 2017). The studies reviewed on TB/HIV
had inadequate information on the association of multimorbidity and mortality among
TB/HIV coinfected patients on ART (Mchunu et al., 2016; Oni et al., 2015; Pepper et al.,
2015).
Bates et al. (2015) and WHO (2018) have indicated that
comorbidity/multimorbidity could be contributing to mortality among TB/HV patients
globally. Oni et al. (2015) and Peltzer (2018) have suggested that comorbidity or
multimorbidity could be associated with mortality among TB/HIV patients in South
Africa. Studies conducted in Uganda show that high mortality among TB/HIV may be
associated with extrapulmonary TB, low CD4 cell count, late presentation, several
comorbidities, and low Karnofsky score (Kirenga et al., 2014, Musaazi et al., 2019). All
the studies I reviewed indicate that multimorbidity among TB/HIV patients may be
associated with mortality. However, none of these studies showed any statistical
significance that comorbidity or multimorbidity contributes to mortality among TB/HIV
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patients on ART (Bates et al., 2015: Kirenga et al., 2014; Musaazi et al., 2019; Oni et al.,
2015). This finding highlights the need for research on the association between mortality
and multimorbidity among TB/HIV patients on ART in Uganda.
The purpose of this study was to test and analyze the association between
multimorbidity, health care processes, and mortality among TB/HIV patients on ART.
The independent variables were multimorbidity, age, sex, marital status, type of TB,
phase of TB treatment, and timing of initiation for ART. For this study, a patient had
multimorbidity if they had any two diseases in addition to TB and HIV. Examples of
these diseases are diabetes mellitus, hypertension, malnutrition, pneumonia, and cancers.
Multimorbidity was measured as yes or no. The dependent variable was mortality.
This chapter includes the literature search strategy, the conceptual framework, and
the literature review. The literature review consists of descriptions, evidence, and
synthesis of the current literature for the last 5 years and classic or relevant literature
beyond 5 years. The literature review includes topics on TB/HIV coinfection, mortality in
TB/HIV coinfected patients on ART, prevalence, and patterns of multimorbidity among
TB/HIV patients on ART. Also, the literature review includes an assessment of
multimorbidity, the effects of multimorbidity on mortality, and a gap in the mortality and
multimorbidity among TB/HIV patients on ART. The last section of this chapter includes
a summary and conclusions about key findings and a transition to Chapter 3.
Literature Search Strategy
I searched electronic databases for individual articles in English, using Google
search engine, Google Scholar, and Thoreau from Walden University. The electronic
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databases included PubMed, CINAHL, Dissertations & Theses at Walden University,
EBSCO ebooks, MEDLINE with full text, Open Library, Science Direct, SAGE
Knowledge, Thoreau Multi-Database Search, and World Health Organization database.
Keywords used during the search included multimorbidity, comorbidity, TB/HIV, ART,
treatment of multimorbidity, opportunistic infections, prevention of comorbidities,
TB/HIV integration, TB, TB/HIV Mortality, TB/HIV deaths, TB/HIV outcomes
multimorbidity conceptual framework, patient outcomes conceptual framework,
multimorbidity, and mortality.
The main articles included in this literature review were published between 2016
and 2020 found mainly in peer-reviewed journals. The journals include AIDS Research
and Treatment, Journal of AIDS and HIV Research, Journal of Infectious Diseases, The
Lancet, Transactions of the Royal Society of Tropical Medicine and Hygiene, and the
Biomed Central Pulmonary Medicine open access New England Journal of Medicine, and
PLoS ONE. I also reviewed articles from the International Journal of Tuberculosis and
Lung Disease, Public Health Action, the Journal of the International Association of
Providers of AIDS Care, the AIDS Journal, International Journal of Mycobacteriology,
and Journal of Acquired Immune Deficiency Syndromes. Also, journals from sub-Saharan
Africa and India were reviewed: the South African Medical Journal, the Ethiopian
Journal of Health Development, and the Indian Journal of Medical Research. I accessed
the relevant articles and applied the snowball method with Google Scholar to access other
papers that have referenced the article to obtain more articles related to multimorbidity
and TB/HIV outcomes. Manuscripts published between 2016 and 2020, within 5 years of
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expected publication, were included. Also, a few relevant classical references outside the
5 years were included.
The identified items were entered into the Zotero database in different folders.
The conceptual framework and all variables had folders in Zotero to ease the writing
processes. Using Zotero, I searched for names of PDF articles that were downloaded but
had not been appropriately cited. The Zotero software was used to make corrections to
the references that were poorly labeled. Cleaning the Zotero database was coupled with
removing duplicates and checking for proper referencing using APA style. The references
for excerpts extracted from websites were entered, and I continued to review and remove
redundant articles while adding relevant items until the literature review was complete.
All folders were merged to form one folder and the reference list was produced using
APA style.
Conceptual Framework
The health outcomes conceptual framework has been used to guide the framework
of this study. The health conceptual framework has been used in research outcomes and
health services research. The framework has four domains that include (a) characteristics
of the health system or health care system, (b) patient characteristics, (c)
care/interventions path or process of care, and (d) outcomes (Canadian Institute for
Health Information, 2008; Sbarigia et al., 2016). According to Sbarigia et al. (2016), the
health system and patient factors are direct predictors of care path (the process of care),
which is, in turn, a direct predictor of health outcomes. Also, the patient factors are direct
predictors of health outcomes (Sbarigia et al., 2016).
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In this section, I explain the four domains of the health outcomes conceptual
framework. The characteristics of the health system or health care system structure have
the process, structure, and quality related factors; these include clinic characteristics and
provider characteristics. The patient characteristics have sociodemographic factors (age,
gender, ethnicity, income, education, marital status, socioeconomic status), risk factors
(genetics; behavior, e.g., smoking, drinking, physical activity and diet; personal
resources, e.g., social support, life stress), laboratory, clinical and health status, and
multimorbidity. For care/interventions, path or process of care including preventive,
pretreatment, treatment, and treatment monitoring. The outcomes include patient-related
issues and health system-related consequences. The patient-related results include health
status: e.g., HRQOLTB treatment outcomes (mortality, LTFU, cure + completed = TSR,
non evaluated, failure), the health related (proxy measure of the health status), e.g.,
hospital admissions, complications, increased health service utilization and non healthrelated, e.g., patient satisfaction. The health system performance-related outcomes
include mortality rates and morbidity rates. Figure 2 shows the health system’s four
domains, patient factors, care path and health outcomes, and the relations and how they
affect health outcomes.
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Figure 1
The Health Outcomes Conceptual Framework

Comorbidities as health outcomes are significant in three significant areas: (a)
clinical care, (b) epidemiology and public health, and (c) health service planning and
financing (Valderas, 2009). Comorbidities usually need to be part of the patient outcomes
measuring quality of life because it defines health status. In the early 2000s,
comorbidities related to TB were measured using general instruments like the Short Form
36 (SF36), Charlson comorbidity index, and the WHO tool (Brown et al., 2015). Specific
TB tools are now available to measure TB-related comorbidities—the FACIT-TB
(Dujaili et al., 2015; Mamani et al., 2014). Based on this framework, the health outcomes
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and health status (comorbidities) were the dependent variable, and the other categories
like patient characteristics formed the outcome variable or independent variable.
The health outcomes conceptual framework has elements developed earlier on by
the Donabedian quality of care framework with a structure, process, and outcomes
(Canadian Institute for Health Information, 2008). Donabedian model refers to the
structure as a setting for care delivery, while the process is the medical interventions and
outcome as the impact on health status outcomes. The outcomes are the result of the
effect of the structure and process. Donabedian’s model has been used to measure and
evaluate the quality of care and health systems’ performance (Canadian Institute for
Health Information, 2008; Donabedian, 2005).
The earlier conceptual framework by Donabedian was later used in research study
outcomes and by the Canadian Institute for Health Information to focus on the four
domains. The four areas include the health system structure, the patient characteristics or
factors, the care path, and outcomes (Canadian Institute for Health Information, 2008;
Donabedian, 2005; Sbarigia et al., 2016). The framework is also related to outcomes
research studies focusing on chronic studies and the hepatitis C outcomes framework
(Canadian Institute for Health Information 2008; Sbarigia et al., 2016). Although the
framework mentions these social determinants of health, it does not exhaust them. It does
not include social determinants for health inequities and political and structural
determinants as explained in the new commission for social determinants of health
(CSDH) WHO conceptual framework (WHO, 2010). The WHO conceptual framework
includes the structural determinants, the social determinants of health inequities and
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social determinants of health and how these affect equity in health and well-being, also
referred to as health outcomes (WHO, 2016). In the WHO conceptual framework, the
health system is one of the social determinants of health. The outcomes conceptual
framework is still relevant because of its simplicity in studying the patient level outcomes
and, in particular, comorbidities, a contributor to the health status in an individual patient.
The critical statements and definitions of the health outcomes conceptual
framework include the health system, the patient factors, care path, and health outcomes.
The health care system structure: This is a mechanism through which patients get health
careThe patient factors: the patient characteristics include social demographics (age, sex,
ethnicity, education, income, marital status, and social, economic attributes), risk factors
like smoking, drinking, physical activity and diet, and expectations or preferences of the
patient. The care path includes interventions; Interventions are what is given to the
patient to change the health care status, and this includes prevention, treatment, and care.
The interventions in this study are anti-TB medicines, ART, and cotrimoxazole
preventive therapy.
The health outcomes are status achieved after the implementation of interventions
(Smith et al., 2017). Health outcomes may be either patient related outcomes or health
system outcomes. Patient related outcomes include health status, health-related measures,
and non-health related measures (Sbarigia et al., 2016). The examples of the healthrelated measures include quality-adjusted life years, disability- adjusted years; healthrelated measures like hospital admissions, complications, or test results; while non-health
related measures like patient satisfaction. At the population level, health system
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performance measures apply at the national level, and the health outcomes include
morbidity prevalence and mortality (Canadian Institute for Health Information, 2008;
Sbarigia et al., 2016).
Outcomes research is varied and focuses on quality, the effectiveness of health as
measured by attainment of specified outcome (Jefford et al., 2003; Shah et al., 2013). The
outcomes include survival, disease status, complications, HRQOL, patient preferences,
quality of care, costs, and mortality. In the past, the health outcomes conceptual
framework has been used in research studies like the management of hepatitis C virus
infection in virology. The framework has also been utilized in the study of chronic
diseases like diabetes in noncommunicable diseases, cancers in oncology, and depression
in mental health (Oni et al., 2015; Sbarigia et al., 2016). Earlier studies done in the 2000s
indicated that the outcomes research was used to assess well-being and satisfaction and
economic analysis. The economic analysis includes cost outcome, cost effectiveness, and
cost utility. The models used in decision analysis should link research results, patient
preferences, and population data (Jefford et al., 2003; Shah et al., 2013). The framework
has been used in clinical trials and other studies. The benefits of outcomes research are
varied, including the consumer, health care provider, health care organization
management, and government (Jefford et al.,2003; Shah et al., 2013).
The benefits include increased participation in decision making for consumers,
certainty about interventions by providers, use of the most cost effective interventions by
health care organizations, and for governments to be able to plan, save on costs, using
effective medicines and research areas (Jefford et al., 2003; Shah et al., 2013). Using this
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health outcome conceptual framework, I tested and analyzed the association between
multimorbidity, health care processes, and mortality among TB/HIV patients on ART in
Uganda. The health outcomes framework was the most appropriate framework to use
because it could be used to explore the relation of multimorbidity with mortality among
TB/HIV patients on ART (Canadian Institute for Health Information, 2008, Sbarigia et
al., 2016).
Literature Review
In this section, I describe the constructs of interest for this study, the chosen
methodology, and methods that are consistent with the scope of the study. The constructs
include the TB/HIV epidemiology, TB/HIV collaboration and the integration of TB/HIV
services, TB/HIV and ART, HIV and TB drug interactions and adverse effects, Mortality
among TB/HIV patients, multimorbidity among TB/HIV patients, determinants and
patterns of multimorbidity, measures of multimorbidity, and later the methods and
methodology consistent with this study.
TB/HIV Epidemiology
In 1993, the WHO declared the DOTS strategy to deal with an increasing TB
global epidemic (WHO, 2016). The DOTS strategy was underpinned by five components
that included political commitment, diagnosis through microscopy, administration of
standardized short course chemotherapy through directly observed therapy, regular
supply of anti-TB medicines, recording and reporting (WHO, 2016). Globally, countries
started implementing the DOTS strategy to detect 70% of the TB cases and cure 85% of
the identified TB patients. There was a noticeably increased TB notifications trend, and
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by 2015, countries had saved 43 million people with TB. However, the increasing TB
patients’ trend was associated with HIV, especially in the 22 high burden countries. It
was evident that the DOTS strategy was not adequate to control TB and WHO replaced
the DOTS strategy with the STOP TB strategy, which had additional components to deal
with the TB/HIV burden and the rising MDR TB (WHO, 2016).
To date, HIV and TB constitute the high burden diseases in low resource settings,
especially in sub-Saharan Africa (Bruchfeld et al., 2015; WHO, 2018). WHO has selected
the 30 TB/HIV high burden countries focusing on the TB/HIV epidemic in these
countries, as showed in the End TB strategy (WHO, 2018). HIV increases the risk of
developing TB to 20 to 40-fold and causes 25% of deaths in TB patients (Bates et al.,
2015). The TB/HIV coinfection in countries like sub-Saharan Africa was about 70%, and
it was inevitable the TB/HIV epidemic needed to be dealt with (Bruchfeld at al., 2015). In
the TB high burden areas in low resource settings, HIV increases susceptibility to TB,
reinfection with TB, and also reactivation of TB. HIV increases progression to TB, while
TB increases the progression from HIV infection to AIDS.
TB/HIV Collaboration and the Integration of TB/HIV Services
To control the dual epidemic, in 2005, WHO developed a TB/HIV framework
with 12 collaborative activities. The three objectives of the TB/HIV collaboration were to
establish mechanisms for TB/HIV collaboration, reduce the burden of TB in HIV patients
and lessen the burden of HIV in TB patients (Ford, & Getahun, 2015; WHO, 2016).
Countries have used this framework to test over 80% of TB patients for HIV and start
over 30 % of TB /HIV patients on ART (Ford, & Getahun, 2015; WHO, 2018).
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Individual countries like Uganda have tested above 90% of TB patients for HIV and
started over 80% of TB/HIV patients on ART (WHO, 2018)
Integration of TB/HIV services has been known to improve TB treatment
outcomes (Mchunu et al., 2016; Musaazi et al., 2019). Five models of integration have
been identified by several studies based on entry at either the TB or HIV service point
with a referral for a service at the other aspect and then offering both services at the same
point in Uganda (Legido-Quigley et al., 2013). Integration of TB/ HIV services has been
found to vary based on the different model’s TB/HIV service delivery from full
segregation of services through partial integration with referral to full integration. Since
no one size fits all, the different models have advantages and disadvantages. The model
with complete segregation with a referral is easy to implement. However, the model has
risks of losing patients, while the one with full integration needs more space and human
resources hosted at the same site. Although the service delivery models have not been
comprehensively compared in the different studies to determine the best model for
delivering TB/HIV services. Uyei et al. (2012) found that co-location of services is
necessary but not sufficient for comprehensive TB/HIV service delivery to occur. Also,
treatment outcomes amidst TB/HIV integration affect comorbidities, side effects, delay of
patients to access treatment, low serum levels, low patient weight, previous TB treatment,
and knowledge on TB treatment (Mchunu et al., 2016; Musaazi et al., 2019). Useful
indicators for monitoring integration, like mortality, need to be selected (Mchunu et al.,
2016). The researchers and practitioners should be extending the collaborative TB/HIV
framework to handle multimorbidity (Oni et al., 2015; WHO, 2018).
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TB/HIV and ART
In many studies, ART has been shown to reduce mortality and improve TB
treatment outcomes by preventing opportunistic infections and restoring immunity with
lifelong viral suppression (Mchunu et al., 2016; WHO, 2018). The TB deaths in TB/HIV
coinfected patients, although not sure, seems to be an indicator that can be used to
monitor TB/HIV integration (Ansa et al., 2012). Clinical studies indicate that ART does
not entirely restore immunity in HIV patients and, therefore, a risk of developing
comorbidities, especially in advanced age (WHO, 2018). Some studies have shown that
mortality is still high in TB/HIV patients on ART. The mortality may be due to
comorbidities and late treatment initiation (Mchunu et al. 2016, Nansera et al., 2012).
Other studies indicate that ART has a protective effect against death in TB/HIV patients
on ART (Pepper et al., 2015). Also, Oni et al. (2015) found that in South Africa, HIV
patients who were on ART had a lower comorbidity index than those not on ART (Oni et
al., 2015). Although ART has protective effects in TB/HIV patients on ART, there is a
need to determine why some TB/HIV patients on ART still die (Mchunu et al., 2016,
Pepper et al., 2015).
HIV and TB Drug Interactions and Adverse Effects
Drug interactions commonly occur in TB/HIV patients on rifampicin. Rifampicin
interacts with nevirapine and efavirenz due to induction of CYPP50. This induction
reduces the bioavailability of both these drugs (Bruchfeld et al., 2015). To mitigate this
effect, the best anti-TB drug to use is rifabutin or the use of efavirenz. Adverse effects are
common in TB/HIV patients on anti-TB treatment and HAART. Adverse effects also
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occur with the use of anti-TB together with ARVs. The common side effect is
hepatotoxicity caused by Rifampicin and Isoniazid; also, ARVs cause this. So, the double
effect may be magnified in some patients causing mortality. HIV patients who start
ARVs late usually experience IRIS; this leads to worsening TB signs and symptoms and
deterioration of the radiographic features on a chest X-ray. Lymphadenopathy is also
common. Treatment with corticosteroids helps in managing the IRIS.
Mortality Among TB/HIV Patients
The initiation of ART among TB/HIV patients led to the improvement of
treatment outcomes. However, despite ART initiation among TB/HIV patients, the
mortality among these patients is high (Mchunu et al., 2016; WHO, 2018). In Swaziland,
the evaluation of the 2010–2013 cohort showed similar findings where about 13% of
TB/HIV coinfected patients were dying despite ART (Mchunu et al., 2016). Similar
findings have also been found in Uganda by Musaazi et al. (2019), where about 10% of
TB/HIV coinfection are still dying. However, in all the studies, the risk factors associated
with the high case fatality rates are not well known.
Multimorbidity Among TB/HIV Patients
Although the definition of multimorbidity has been differing over the years, the
AMS has defined multimorbidity as the coexistence of two or more chronic diseases or
conditions (AMS, 2018). Patients with multimorbidity have an increased risk of
premature death, high hospitalization, high costs of care, and low quality of life (AMS,
2018; Violan et al., 2014).
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The prevalence of multimorbidity is increasing in both developed and developing
countries. Oni et al. (2015) showed that multimorbidity is high in TB/HIV patients in
South Africa and indicating that NCDs are occurring alongside infectious diseases. HIV
is known as comorbidity among TB patients. Patients with HIV usually have other
coinfections in addition to TB, leading to multimorbidity. In TB/HIV patients,
Multimorbidity is one of the factors postulated to lead to death among TB/HIV patients
(Mchunu et al., 2016; Musaazi et al., 2018). The higher the number of comorbidities, the
greater the chance of mortality (Lix et al., 2016). According to Nunes et al. (2016).
Multimorbidity is associated with an increase in the risk of death mortality. However,
Schäfer et al. (2018) indicated that the effect of multimorbidity on mortality is still
disputed. Earlier studies by Haregu et al. (2012) showed that mortality may be associated
with multimorbidity, gender, age, education status, income, and social, economic status.
Determinants and Patterns of Multimorbidity
There are well known determinants of multimorbidity that include age, gender,
and low socioeconomic status. Multimorbidity has been associated with increasing age,
although studies in Africa show that young age is also associated with multimorbidity
(AMS, 2018; Oni et al., 2015). Females are highly associated with multimorbidity than
males, as shown by Violan et al. (2014). However, studies in sub-Saharan Africa show a
mixed picture where for some diseases, the prevalence is more in males than females
while in others, it is more in females than males (Oni et al., 2015). The low socioeconomic status, as measured using the deprivation index, educational level, and health
insurance coverage, is significantly associated with multimorbidity (Violan et al., 2014).
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Usually, the patterns of multimorbidity are determined by the most prevalent
conditions in a given geographical location. In European countries and the US, the typical
multimorbidity patterns are hypertension and osteoarthritis or cardiometabolic conditions
(Violan et al., 2014). In sub-Saharan Africa, it is becoming clear that there is a dual
burden on non communicable and infectious diseases, and this constitutes the patterns of
multimorbidity. Oni et al. (2015) observed the typical patterns of multimorbidity in South
Africa included hypertension, diabetes, HIV, and TB. (Oni et al., 2015). The high
prevalence of chronic and infectious diseases in sub-Saharan Africa confirms the ongoing
epidemiological transition in the region and the need to reexamine the way
multimorbidity are treated in primary health care centers (Oni et al., 2015)
Measures of Multimorbidity
There are various types of measuring multimorbidity. Haregu et al., (2012)
indicated two conventional approaches to measuring multimorbidity, namely using a
single condition and clustering of diseases into nonrandom group. According to Lefèvre
et al. (2014), there are four types of measures of multimorbidity. The measure includes a
simple count of chronic diseases. The second method is grouping diseases from a given
list as dyads or triads; identifying common groups with the same diseases and
characteristics, the third includes identifying an index disease first, and the fourth
includes identifying homogenous groups of people with similar characteristics and
similar diseases (Lefevre et al., 2014).
According to Wallace et al., (2016), three standard comorbidity measures have
been used in research to measure comorbidities. The measures include the following. (a)
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count based morbidity measures involving a simple count of chronic diseases. (b)
Charlson comorbidity index, based on a list of 17 conditions (Lix et al., 2016; Wallace,
McDowell, Bennett, Fahey, & Smith, 2016). Each condition assigned a weight of 1 to 6,
with zero indicating no comorbidity. (c) Other similar measures used to measure
comorbidity are RXRisk comorbidity assessment, Elixhauser Comorbidity Index and
Johns–Hopkins Adjusted Clinical Group® (ACG®), Chronic Disease Score, Number of
Diagnoses and Number of Prescription Drugs Dispensed. The tools use data from patient
charts or electronic medical records. Some authors had pointed out that although
comorbid measurements have been around for some time, there was no validated tool for
TB that measures health status or comorbidities (Brown et al., 2015). However, from the
ongoing discourse, there are still varied ways of measuring multimorbidity based on
different authors. Therefore, a careful review of the measurements and application would
be prudent.
Most of the multimorbidity studies have focused on the prevalence, patterns, and
determinants of multimorbidity (Violan et al., 2014). The most common design for
studies is the cross-sectional design (AMS, 2018; Oni et al., 2015). Patients in
multimorbidity studies have been identified through self-reporting illness or extraction of
data from electronic medical records. There are several methods used in multimorbidity
studies, as indicated in the following paragraph.
The patterns of multimorbidity in several studies have been analyzed using cluster
analysis and factor analysis (Violan et al., 2014). While analyzing determinants like
socioeconomic class, the studies have used odds ratios. The test used to test patterns
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include λ2 to measure the difference in the prevalence of chronic disease and
multimorbidity. The tests used to test for significance include the Shapiro-Wilk test used
to test normality and the Kruskal Wallis test to test for significance of non parametric
continuous variables. Significance testing was done in some studies using 2-sided p
values and 95% confidence intervals.
An increasing number of research on multimorbidity have been conducted since
the 2000s (Oni et al., 2015; Van den Akker et al., 2001). Researchers described how
research on multimorbidity should be conducted with a highlight the selection of the set
of comorbid diseases to measure, and these should be the more prevalent diseases in a
given study setting (Van den Akker et al., 2001; Cassell et al., 2018). The research on
multimorbidity has focused on four primary areas the magnitude of multimorbidity
(incidence and prevalence), the patterns which focus on the clustering of multimorbidity,
the severity that focuses on frailty, and determinants of multimorbidity that include age,
gender, and socioeconomic status (Oni et al., 2015; Weimann et al., 2016).
The approach used broadly to investigate these issues is the quantitative
approach. The quantitative approach has three broad areas that include data collection,
data analysis, and interpretation. Data collection for multimorbidity has been done either
through self-report, interview questionnaires, or data extraction from existing databases
(Casell et al., 2018). The following methods are used in data analysis, counts, analysis
using multiple regression, stratified analysis according to Mantel Haenzel, or stepwise
multiple logistic regression (Van den Akker et al., 2001). Also, relative risk or odds ratio,
confounding variables like age, socioeconomic status, environmental factors, and
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psychological factors should be taken care of as confounders and effect modifiers (Van
den Akker et al., 2001).
In recent research, researchers have mostly used retrospective cross-sectional
designs to explore comorbidities (Casell et al., 2018; Creswell et al., 2011; Oni et al.,
2015; Pepper et al., 2015). There are some strengths in using retrospective cross-sectional
designs. The use of retrospective cross-sectional designs may be attributed to the fact that
prospective designs take a long time, and an instant study would have limited data.
Therefore, retrospective designs are used because they are quick to perform as compared
to prospective studies. In multimorbidity studies, researchers usually require large sample
sizes that are difficult to obtain with prospective studies within a short period. The
retrospective cross-sectional studies have the advantage of collecting large volumes of
data in a short time (Casell et al., 2018; Weimann et al., 2018). Also, retrospective studies
require a lower cost as compared to prospective studies. Usually, the costs of prospective
designs as compared to retrospective designs are high and inhibitive (Creswell et al.,
2011).
Although retrospective studies have been used to examine multimorbidity, they
have inherent weaknesses like a lack of variables that may be useful to consider (Umanah
et al., 2015). Retrospective designs usually depend on already collected data from
medical records and may collect all the relevant variables, including confounders
(Umanah et al., 2015; Weimann et al.; 2016). However, some previous studies extracting
data from electronic registers may have lacked variables like CD4 cells, date of initiation
of treatment because these were missing in those databases (Oni et al., 2015). In this
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study, because of the limitations of time and cost of the survey, I used retrospective
cohort records to review the design with the quantitative design. In the past,
multimorbidity has been defined in various ways, and therefore, it was difficult to
compare studies. After 2018, the AMS (2018) has defined multimorbidity to mean the
coexistence of two or more chronic conditions of long duration physical non
communicable disease, mental condition on infectious disease (AMS, 2018). The new
definition means that the comparison of studies would no longer be a limitation to
multimorbidity studies.
Justification of Selected Variables or Concepts
The selection of independent and dependent variables was based on gaps
observed in the existing literature of the variables as elaborated in the conceptual
framework and the literature reviewed on multimorbidity (Oni et al., 2015; Weimann, et
al., 2016). Also, the variables were best on the best predictors of outcomes based on
previous literature.
The independent variables are multimorbidity, and a group of multimorbidity was
selected: diabetes mellitus, hypertension, malnutrition, pneumonia, cancers. The author
based the multimorbidity selection on the frequent multimorbidities documented in TB
patients in sub-Saharan Africa and Uganda (Oni et al., 2015; WHO, 2018). The
dependent variable is mortality. This variable was selected because mortality is
associated with multimorbidity. However, there is no study for TB/HIV that has
associated mortality with multimorbidity (Mchunu et al., 2016). This study is likely to
give insights into the association between mortality and multimorbidity. Covariables for
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this study selected include age, gender, income, education, marital status, and social,
economic status (Mchunu et al., 2016; Pepper et al., 2015). These covariables are always
included in other studies of multimorbidity (AMS, 2018). Most multimorbidity is
attributed to gender, age, and low socioeconomic class. (Violan et al., 2014). The next
section comprises the literature on each of the variables. Independent variables included
multimorbidity, age, sex, marital status, phase of TB treatment, the timing of ART
initiation, and type of TB. The dependent variable was mortality.
This section describes the literature for all the study variables that are within the
last 5 years. However, important literature that goes beyond 5years is also included. The
literature covers, what is known, the gap, and what this study may contribute to the
existing body of knowledge for TB/HIV patients on ART. The variables of the study
include mortality, which is a dependent variable. The rest of the variables are
independent variables. They include multimorbidity, demographic factors (sex, age, and
marital status), the phase of TB treatment (Initiation and continuation), the time of
initiation of ART, and the type of TB.
Mortality Among TB/HIV Patients on ART
An increasing number of researches on mortality have been conducted since the
2000s (Mchunu, et al., 2016; Oni et al., 2015;). The research on TB/HIV mortality has
focused on TB/HIV patients in general and not necessarily on ART alone, sociodemographics clinical and immunological information as independent variables, and
mortality as the dependent variable (Mchunu et al., 2016; Musaazi et al., 2019; Stijnberg
et al., 2019; Tola et al., 2019;). The primary outcomes of these study show that ART is
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protective for TB patients, and death is usually associated with patients who are not on
ART, with adverse effects, and who begin ART late variable (Mchunu et al., 2016;
Musaazi et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;).
The initiation of ART among TB/HIV patients led to the improvement of
treatment outcomes. However, despite ART initiation among TB/HIV patients, the
mortality among these patients is high (Mchunu et al., 2016; Musaazi et al., 2019; WHO,
2018). In Swaziland, the evaluation of the 2010 – 2013 cohort showed similar findings
where about 13% of TB/HIV coinfected patients were dying despite ART (Mchunu et al.,
2016). Similar findings have also been found in Uganda by Musaazi et al. (2019), where
about 10% of TB/HIV coinfection are still dying. However, in all the studies, the risk
factors associated with the high case fatality rates are not well known.
Mortality as a Dependent Variable
Mortality has been indicated as an outcome of multimorbidity (AMS, 2018; Smith
et al., 2017). Multimorbidity has worse consequences, including mortality, disability,
institutionalization, greater use of health care, miserable quality o life, and high side
effects (Vetrano et al., 2017). Mortality in TB/HIV coinfected patients remains high
globally despite the implementation of the test and treat policy for ART among TB/HIV
patients. The link between mortality and multimorbidity among TB/HIV patients is not
well understood. I explored the link between multimorbidity, health care processes, and
mortality among TB/HIV patients on ART. One of the studies conducted in Denmark
showed high death among people with multimorbidity was male, single or unmarried,
low income status, and high age of 60 to 70 years (Taleshan et al., 2018).
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Multimorbidity Among TB/HIV Patients
Although the definition of multimorbidity has been differing over the years, the
AMS (2018) defines multimorbidity as the coexistence of two or more chronic diseases
or conditions (AMS, 2018). Patients with multimorbidity have an increased risk of
premature death, high hospitalization, high costs of care, and low quality of life (AMS,
2018; Violan et al., 2014). According to Nunes et al. (2016), multimorbidity is associated
with an increase in the risk of mortality. However, Schäfer et al. (2018) indicate that the
effect of multimorbidity on mortality is still disputed. The prevalence of multimorbidity
is increasing in both developed and developing countries. Oni et al. (2015) showed that
multimorbidity is high in TB/HIV patients in South Africa and indicating that NCDs are
occurring alongside infectious diseases. HIV is known as comorbidity among TB
patients. Patients with HIV usually have other coinfections in addition to TB, leading to
multimorbidity. In TB/HIV patients, multimorbidity is one of the factors postulated to
lead to death among TB/HIV patients (Mchunu et al., 2016; Musaazi et al., 2018). The
higher the number of multimorbidities, the greater the chance of mortality (Lix et al.,
2016). The gap in this study is that there is little literature that multimorbidity is
associated with mortality among TB/HIV patients on ART (Mchunu et al., 2016; Musaazi
et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;). In this study, I determined the
association between multimorbidity (non communicable disease clusters like diabetes,
hypertension, malnutrition, cancers, and others.) and mortality among TB/HIV patients
on ART.
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Several patterns of multimorbidity exist in different parts of the world. In Europe
and the USA, several studies indicated the most common multimorbidity patterns. The
most common multimorbidity patterns were cardiometabolic and cardiovascular. Others
included metabolic, cardiorespiratory pattern, metabolic pattern, neuropsychiatric, and
musculoskeletal (Vetrano et al., 2017; Violan et al., 2014). In developing countries where
both infectious and non communicable diseases exist the especially in sub-Saharan
Africa, because of the ongoing epidemiological transition, the multimorbidity pattern was
mixed with hypertension, diabetes, HIV, and TB (Oni et al., 2015). For this study, which
was conducted in Uganda found in sub-Saharan Africa, the independent variables were
multimorbidity, age, sex, marital status, phase of TB treatment, the timing of ART
initiation, and type of TB, while the dependent variable is mortality (Mchunu et al., 2016;
Pepper et al., 2015). The following sections describe the essential constructs and
variables that were used in this study.
Diabetes Mellitus
Globally, the prevalence of diabetes is increasing, and patients with diabetes are at
higher risk of multimorbidity. Patients with diabetes are at increased risk of
cardiovascular, cerebrovascular diseases, pulmonary TB, kidney disease, dementia, and
depression leading to premature illness and death (Chen et al., 2016). In countries with
limited resources, the incidence of TB is declining while the number of notified cases of
diabetes mellitus is rising, giving rise to a double burden (Bates et al.,2015; Kapur &
Harries, 2013; Reis-Santos et al., 2013; Ugarte-Gil & Moore, 2014). The WHO studies
reveal that diabetes is the second common comorbidity after HIV in patients with TB
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(WHO, 2015). There could be variations by country based on the prevalence of TB; high
TB burden countries are likely to have HIV as comorbidity, while in those countries
where the HIV prevalence is low, diabetes is likely to be the most prevalent comorbidity,
especially in populations above 65 years (Brown et al., 2015). In Asia, Ko et al. (2016)
found that the prevalence of TB among TB patients had increased by 27% over the 10
years 2000 to 2010 (Ko et al., 2016). To manage the TB and diabetes comorbidity, WHO
has created a framework similar to the TB/HIV framework (Sharma et al., 2014). The
primary objectives are, establish mechanisms for collaboration, detect and manage TB in
patients with diabetes, and identify and manage diabetes in patients with TB. Also, a
monitoring framework has been developed to ensure surveillance (Bates et al., 2015).
Brown et al. (2015) explained the misdistribution of fat (lipodystrophy) in HIV patients
on non nucleoside reverse transcriptase inhibitors in patients with diabetes,
hyperglycemia, and obesity are some of the comorbidities that manifest in the HIV
patients on ART. (Brown et al., 2015). Higher mortality is observed in patients with more
types of comorbidities (Oni et al., 2015).
Hypertension
TB and cardiovascular diseases have been noted to have links, although
cardiovascular conditions are not direct risk factors for TB (Creswell et al., 2011). The
effects of TB on the lungs have been known to give rise to pulmonary hypertension
(Creswell et al., 2011). In studies conducted in South Africa, hypertension was found to
be the most prevalent comorbidity in both diabetic and HIV patients (Oni et al., 2015;
Weimann et al., 2016). The most common comorbidity among TB patients was
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HIV/ART, followed by hypertension and diabetes (Oni et al., 2015; Weimann et al.,
2016). The epidemiological transition is eminent in low-resource settings, where more
non communicable diseases, including hypertension, are becoming prevalent with an
equally high burden of communicable or infectious diseases (Creswell, 2011; Weimann
et al., 2016). The dual burden of infectious and non infectious diseases may indicate the
need to conduct more studies. Such e studies should explore the links of hypertension
with TB focusing on high TB burden settings (Weimann et al., 2016).
Malnutrition
Malnutrition is associated with mortality in patients with multimorbidity,
contributing to 10-85% of patients with multimorbidity. Mini nutritional assessment may
be an easier way of measuring nutritional status in patients with multimorbidity. Usually,
there are 18 items, but these are reduced to 7, including weight loss, mobility, body mass
index, number of full meals, mode of feeding, fluid consumption, and health status. The
new indices are 12.5–15 represents well-nourished, 9–12 represents those at risk of
malnutrition, and less than nine those who are malnourished.
Pneumonia
Pneumonia is one of the comorbid diseases found in patients with multimorbidity,
especially the elderly. The elderly with multimorbidity have pneumonia called
community-acquired pneumonia. The risk of pneumonia is high in frail elderly
hospitalized patients. The most frequent type of pneumonia that affects the adult is
Streptococcus pneumonia. About 45% of all the cases of community-acquired pneumonia
occur in the elderly above 65 years. To avoid pneumonia in the elderly, issues around
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lifestyle, including immunization in the elderly, have to be considered. Mortality due to
pneumonia in the elderly is 25% higher than in the general population.
Cancers and Mental Health
Cancers increases with age, and the increase in age is associated with
multimorbidity. In patients above 65 years, more cancers and other multimorbid diseases
are usually common (AMS, 2018). However, there are few studies on cancers and
multimorbidity. Taking care of multimorbidity in cancer patients could be crucial since
multimorbidity increases in patients with cancer and risk factors such as smoking,
obesity, and alcohol use (AMS, 2018). The common multimorbidity includes myocardial
infarction, osteoporosis, stroke, and metabolic syndrome. Mortality, quality of care, and
treatment complications need to be taken care of in such cancer patients. Multimorbidity
is associated with mental health. People with mental health have a 25-year life
expectancy less than the other individuals. Mental health can be measured using
depression (AMS, 2018). There is a detailed questionnaire that has been developed over
time used to assess mental health.
Age, Gender, and Socioeconomic Status and Mortality
There are well known determinants of mortality that include age, gender, and low
socioeconomic status. Earlier studies by Haregu et al. (2012) showed that mortality may
be associated with gender, age, education status, income, and social, economic status .
Mortality has been associated with increasing age, although studies in Africa show that
young age is also associated with mortality in TB/HIV patients (AMS, 2018; Oni et al.,
2015). Females are highly associated with mortality than males, as shown by Violan et al.
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(2014). However, studies in sub-Saharan Africa show a reversed picture where males die
more than females in TB/HIV patients (Oni et al., 2015). The low socioeconomic status,
as measured using the deprivation index, educational level, and health insurance
coverage, is significantly associated with mortality (Violan et al., 2014). The current gap
is that there is little evidence in sub-Saharan Africa about the association of mortality
with age, mortality, and marital status among TB/HIV patients on ART (Mchunu et al.,
2016; Musaazi et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;). In this study, I
analyzed the association between demographic factors (sex, age, and marital status) and
mortality among TB/HIV patients on ART.
TB Treatment Phase and Mortality
Patients diagnosed with susceptible TB take treatment for 6 months during the
initial phase and continuation phase. The initial phase of TB treatment consists of 2
months of treatment. The initial phase has 4medicines: a fixed dose of rifampicin,
isoniazid, pyrazinamide, and ethambutol (WHO, 2018). The combination of medicines
kills the tubercle bacilli rapidly, and the patient becomes non infectious in about 2 weeks,
and symptoms subside (WHO, 2013). PBC patients rapidly become sputum negative by
the end of 2 months. These medicines are highly effective in HIV and non-HIV patients
who may harbor a sizeable bacillary load. The continuation phase is given for 4 months
with rifampicin and Isoniazid (WHO, 2018). Studies indicated that mortality is high in
patients in the initial phase, especially at 2 months (Musaazi et al., 2019; Stijnberg et al.,
2019; Tola et al., 2019;). However, these studies do not necessarily comment on the
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initial or continuation phase (Mchunu et al., 2016; Musaazi et al., 2019; Tola et al.,
2019).
Most of these studies point out that these patients with high mortality at 2 months
may not be on ART. Mortality at 2 months may also be due to delayed diagnosis and the
start of TB treatment (Stijnberg et al., 2019; Tola et al., 2019;). This finding indicates a
gap in the knowledge of what happens in the era of ART, test, and treat policy. Are
patients still dying at 2 months in the initial phase, or are they dying in the continuation
phase? There is a need to explore when mortality happens in patients initiated on ART
and then develop TB, and even those who begin ART after TB treatment. This study
analyzed the association between TB treatment (Initiation and continuation phase) and
mortality among TB/HIV patients on ART. The phase of TB treatment was the
independent variable, while mortality was the dependent variable, and all these were
categorical variables. Also, the analysis indicates those who died either in the initial or
continuation phase and when they started ART.
Time of initiation of ART and Mortality Among TB/HIV Patients
Delay in ART initiation is one of the associations of mortality in TB/HIV patients,
yet accelerated ART initiation improves clinical outcomes (Ford et al., 2018; Lisboa et
al., 2019). Some earlier studies had shown that health workers could delay ART in those
with less risk of IRIS and adverse reactions (Tola et al., 2019; Lisboa et al., 2019).
However, in those studies, ART was only indicated in patients with a CD4 cell count of
less than 200. However, mortality has continued to be high among patients with TB/HIV
on ART (Gatechompol et al., 2019; Musaazi et al., 2019; WHO, 2018). During 2012, the
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recommendation of when to start ART in TB/HIV patients became very important
(Gatechompol et al., 2019).
In 2013, WHO produced a test and treat policy, and for all TB/HIV patients,
ART was to begin within 8 weeks of the TB patients beginning TB treatment
(Gatechompol et al., 2019). On the other hand, patients who have HIV and are on ART
can still develop TB. However, no known studies were found which indicate the
association between time of initiation of ART (before the start of TB treatment and after
the start of TB treatment) and mortality among TB/HIV patients on ART, and this is a
gap. This study was used to determine the association between time of initiation of ART,
before the start of TB treatment and after the start of TB treatment, and mortality among
TB/HIV patients on ART. The results could contribute to the body of knowledge of the
time of initiation of ART and mortality.
Type of TB and Mortality Among TB/HIV Patients
TB is either extrapulmonary or pulmonary TB (WHO, 2019). Most of the patients
with TB are usually pulmonary. The pulmonary TB patients are either pulmonary
bacteriologically confirmed (PBC) or pulmonary clinically diagnosed (PCD). The
pulmonary bacteriologically confirmed that people with TB include diagnosis using
microscopy GeneXpert, culture, and other molecular tests. The diagnosis of a pulmonary
clinically diagnosed patient is based on the appearance of radiological abnormalities
suggestive of TB. The patient is usually bacteriologically negative. Also, the PCD
diagnosis can be made based on the judgment of a health worker who decides to start
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treatment with a high suspicion of TB. High mortality among TB/HIV patients was
usually associated with PCD and extrapulmonary TB (Lisboa et al., 2019; WHO, 2006).
Mortality in EPTB and PCD is associated with the delay in diagnosis and delay in
treatment of TB (Lisboa et al., 2019). However, the findings are now mixed, with some
studies showing an association of high mortality with PBC, PCD, and EPTB, while other
studies show the contrary (Lisboa et al., 2019; Tola et al., 2019). A significant number of
these studies were conducted when ART was only recommended in patients with a CD4
cell count of less than 200 (Lisboa et al., 2019; Stijnberg et al., 2019: Tola et al., 2019).
The current literature gap points out inadequate information about the type of TB and its
association among TB/HIV patients on ART during the test and treats all TB/HIV
patients on ART (Tola et al., 2019). This study examined the association of type of TB
with mortality among TB/HIV patients on ART. The study provided new information to
add to the body of existing knowledge for TB/HIV associated mortality.
Summary and Conclusions
Uganda is a high TB/HIV country among the 30 high burden TB/HIV countries in
the world with poor TB treatment outcomes (WHO, 2018). The country still records high
mortality of about 13% among TB/HIV coinfected patients on ART despite the high ART
coverage (MoH, 2018; Musaazi et al., 2019; WHO (2018). The current studies on
multimorbidity show that mortality is a core outcome of multimorbidity. The studies also
highlight the fact that there is inadequate literature on multimorbidity in middle- and lowincome countries (Catala-Lopez et al., 2018; Smith et al., 2018; Xu, Mishra, & Jones,
2017). The studies reviewed on TB/HIV had inadequate information on the association of
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multimorbidity and mortality among TB/HIV coinfected patients on ART (Mchunu et al.,
2016; Oni et al., 2015; Pepper et al., 2015).
In studies conducted globally by Bates et al. (2015) and WHO (2018) indicate that
multimorbidity could be contributing to the mortality among TB/HV patients. Oni et al.
(2015) and Peltzer (2018) suggest that comorbidity or mortality could be associated with
mortality among TB/HIV patients in South Africa. Studies conducted in Uganda show
that high mortality among TB/HIV may be associated with several factors. The factors
include extrapulmonary TB, low CD4 cell count, late presentation, several comorbidities,
low Karnofsky score (Kirenga et al., 2014, Musaazi et al., 2019). All the studies reviewed
indicate that multimorbidity among TB/HIV patients may be associated with mortality.
However, none of these studies shows any statistical significance that comorbidity or
multimorbidity contributes to mortality among TB/HIV patients on ART (Bates et al.,
2015: Kirenga et al., 2014; Musaazi et al., 2019; Oni et al., 2015). The preliminary
finding highlights the need for research on the association between mortality and
multimorbidity among TB/HIV patients on ART in Uganda.
The purpose of the study was to test and analyze the association between
multimorbidity, health care processes, and death among TB/HIV patients on ART. One
of the independent variables is multimorbidity. In this study, a patient has multimorbidity
if they have any two diseases in addition to TB and HIV. Examples of these diseases are
diabetes mellitus, hypertension, malnutrition, pneumonia, cancers. Multimorbidity was
measured as yes or no. The other independent variables include demographic factors
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(age, sex, and marital status), phase of TB treatment time of initiation of ART. The
dependent variable is mortality.
In this study, the health outcomes conceptual framework has been used. The
framework has four domains: health care system, patient characteristics, care or
interventions, and outcomes, and has components derived from the Donabedian model of
quality improvement. (Canadian Institute for Health Information, 2008; Sbarigia et al.,
2016). In the past, multimorbidity in TB was measured using TB non specific tools. The
tools used are the counting method, SF-36, Charleson comorbidity index, among others.
However, new tools specific to measuring multimorbidity in TB like FACIT –TB are
now available and should be utilized and refined.
Worldwide a significant proportion of TB/HIV patients has been started on ART.
However, many of them still die; this highlights the gap that warrants further
investigation, mainly focusing on multimorbidity as one of the likely causes of the
associated mortality. This study could fill the literature gap by the author testing the
association between multimorbidity and mortality among TB/HIV patients on ART and
make recommendations that can be taken up by the policymakers and practitioners. The
literature review would guide the next chapter on research methods, including the
research design and rationale, the methodology, sampling and sampling procedures,
procedures for recruitment, participation, and data collection.
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Chapter 3: Research Method
Introduction
TB/HIV coinfected patients are initiated on life saving ART. However, mortality
has remained high among TB/HIV patients globally and in sub-Saharan Africa (Mchunu
et al., 2016; Oni et al., 2015; Pepper et al., 2015; WHO, 2018). There is inadequate
information about multimorbidity in middle-income and lower-income countries,
including Uganda (Catala-Lopez et al., 2018). As stated in Chapter 1, the purpose of this
quantitative study was to test and analyze the association between multimorbidity, health
care processes, and mortality among TB/HIV patients on ART in Uganda. The major
sections of this chapter include research design and rationale, the methodology, sampling
and sampling procedures, procedures for recruitment, participation, data collection for
secondary data, instrumentation and operationalization of constructs, data analysis plan,
threats to validity, and ethical procedures. This chapter concludes with an overall
summary of the research methods.
Research Design and Rationale
In this study, the independent variables were multimorbidity, age, sex, marital
status, phase of TB treatment, initiation of ART after the start of TB treatment, and type
of TB. Multimorbidity included diabetes, hypertension, malnutrition, cancers, and other
multimorbidities. These multimorbidities were selected based on their occurrence in subSaharan Africa, as indicated in the literature review (Oni et al., 2016; Peltzer, 2018). The
dependent variable was mortality. I used a quantitative cross-sectional design with a
review of medical records. The medical records have data elements for TB and HIV
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patients in all hospitals and some health centers in Uganda. The records are collected
during the clinical review of patients by hospital staff. The HIV data are first collected on
the patient ART card and later entered into electronic medical records. TB patients’ data
are entered into the Unit TB register after a patient is diagnosed with TB and initiated on
treatment. The following are the research questions studied using the cross-sectional
design and review of records:
RQ1: What is the association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART?
RQ2: What is the association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART?
RQ3: What is the association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART?
RQ4: What is the association between time of initiation of ART (before the start
of TB treatment and after the start of TB treatment) and mortality among TB/HIV
patients on ART?
RQ5: What is the association between type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among
TB/HIV patients on ART?
The constraints associated with the cross-sectional design and review of records
are varied and include missing data elements. This constraint is compensated for by using
large volumes of data and eliminating the data with missing variables. Usually, accessing
secondary data that needs extraction is cumbersome because it needs approvals at many
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levels. However, this challenge was sorted out by ensuring the MoH issued a letter of
introduction to the regional referral hospitals. The letter identified the request for the data
for research.
The cross-sectional design, coupled with a secondary review of the medical
records, ensured easy access to large volumes of data collected over a long period. The
costs to collect primary data were saved. Also, it is ethical to use the existing secondary
data instead of trying to collect primary data from patients affecting their physical or
mental well-being (Laureate, 2012). Over the last two decades, multimorbidity data have
been collected through either interview of patients or review of medical records. For
example, recent multimorbidity studies by Peltzer (2018), Weimann et al. (2016), Oni et
al. (2015), and Pepper et al. (2015) were conducted using cross-sectional designs and
reviews of records. Cross-sectional studies are known for describing variables and
distribution of patterns and examining associations between predictors and outcomes
(Hulley, 2007). Cross-sectional studies and reviews of records have been used to build
the body of existing knowledge on multimorbidity and therefore were suitable for this
study (AMS, 2018; Rudestram & Newton, 2015).
Methodology
Population, Sampling, and Sampling Procedures
The target population of this study was TB/HIV patients on ART in Uganda. In a
year, about 17,000 TB/HIV patients are notified in Uganda (WHO, 2016). For this study,
the accessible population was the TB/HIV patients on ART in the Unit TB register and
ART cards or HIV electronic medical records at the national and regional referral
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hospitals in Uganda. The intended sample of the study was TB/HIV patients enrolled on
ART in selected hospitals in Uganda. The patients were registered in TB and ART cards
or HIV electronic medical records in Uganda between January 2017 and December 2019.
Systematic sampling was conducted to reach the intended number of regional hospitals.
Nine out of the 14 regional referral hospitals with the corresponding sample size of
available patients were selected. Data for TB/HIV patients on ART were extracted for all
TB/HIV adults and children from January 2017 to December 2019 from the selected nine
hospitals.
Inclusion and Exclusion Criteria
The sampling included TB/HIV patients on ART in selected regional referral
hospitals registered in the Unit TB registers and ART client cards between 2017 and
2019. All TB/HIV patients on ART were included in the sample. The data were
abstracted from the TB registers and ART cards for 2017–2019 for all TB/HIV patients.
For TB/HIV patients whose records were missing some vital data, elements were
excluded from the study. The patients who did not meet the criteria were excluded from
the study.
Using Power Analysis to Determine Sample Size
I used G Power Version 3.1.9.2 to determine the minimum sample size for logistic
regression for a dichotomous predictor, a significant predictor of a binary outcome
(mortality), with or without other covariates (Faul et al., 2009). The following
information, including statistical power, alpha, and effect size, was used. Usually, the
statistical power of 80% (0.8) is recommended to test a relationship between the
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independent and dependent variables. For alpha, I used a predetermined figure of 0.05 to
maintain the high power of the study. Pr (Y = 1 | X = 1) H1, and I assumed the
probability of mortality for TB/HIV patients on ART with multimorbidity is H1 = 0.18.
Then Pr (Y = 1 | X = 1) H0 = the probability of mortality (Y = 1) when someone has no
multimorbidities. If the probability of mortality for patients without multimorbidity is H0
= 0.09 (TB patients without HIV), the two probabilities give an odds ratio of 2.524. Then
R squared (R2 other X) = the expected squared multiple correlation coefficient (R
squared) between the main categorical predictor (multimorbidity status) and all other
covariates. R squared represents the amount of variability in the main predictor
(multimorbidity) that is accounted for by the covariates. X param π = The proportion of
multimorbidity cases and are dead; this is estimated at 0.5. The sample size was 2,405.
Assuming 20% (481) of the data were missing variables, the sample size would be
adjusted to compensate for the missing variables. The new sample size was adjusted to
2,886, representing 62,362 TB/HIV patients on ART in Uganda from 2017–2019. Table 1
shows the output of the G Power.
Table 1
Calculation of Sample Size using G Power
No.
1
2
3
4
5
6
7
8
9

Parameter
Tails
Pr(Y=1/X=1) H1
Pr(Y=1/X=1) H0
Alpha
R2 other X
X distribution
X Parm π
Critical z
Total sample

Result
2
0.18
0.09
0.05
0.81
binomial
0.5
1.9596640
2,405
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Archival Data/Secondary Data
Recruitment, Participation, and Data Collection
In the study, I used existing secondary data at the regional referral hospitals as
medical records for TB and HIV patients. These secondary data were from the Unit TB
register and ART cards. The primary data are usually collected during routine evaluations
of TB and HIV patients; a clinician enters the data on the ART card or Unit TB registers.
The Unit TB register has the following variables: (a) name and contact of the person, (b)
health worker, (c) age, (d) sex, and (e) address (district, county, subcounty, parish,
village). There is a column for disease classification—in this case, type of TB. Pulmonary
bacteriologically confirmed (PBC) TB occurs in the lungs and is identified through smear
microscopy or molecular technology. Pulmonary clinically diagnosed (PCD) TB occurs
in the lungs but cannot be identified through smear microscopy or molecular technology.
Extrapulmonary (EP) TB occurs outside the lungs. There is also a column for the type of
patient (new, relapse, failure; loss to follow up; treatment history unknown); date
treatment started and regimen, transfer in, results of sputum and other results, TB/HIV
activities (CT, HIV result, CPT, ART) IPT, treatment model (community or facility),
issue of anti-TB drugs (intensive/continuation phase), treatment outcome (cured,
completed, failure, died, transferred out, loss to follow up, diagnosed with DR–TB).
Among the data elements listed, a few data elements were collected from the Unit TB
registers at the regional referral hospitals. The data on independent variables and the
dependent variable were collected from the Unit TB register and ART cards.
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Study Variables
The selection of independent and dependent variables for this study was based on
gaps observed in the existing literature of the variables as elaborated in the conceptual
framework and the literature reviewed on multimorbidity (Oni et al., 2015; Weimann et
al., 2016). Also, the variables of the best predictors of outcomes were based on previous
literature. In the section below, I describe all the variables. The variables include
measurement, type of variable, and the tool used to extract it.
Dependent Variables
The dependent variable is mortality and is measured by yes or no and is a
categorical variable.
Table 2
The dependent variable, measure, type, and tool
Dependent variable

Measurement

Type of variable

Tools to use

Mortality

Yes/No

Categorical/nominal

Data retrieval form

Independent Variables
The independent variables are multimorbidity, age, sex, marital status phase of
TB treatment, initiation of ART after the start of TB treatment, and type of TB.
Multimorbidity includes diabetes, hypertension, malnutrition, cancers, asthma, peptic
ulcer disease, and others. The different multimorbidities were selected based on their
occurrence in sub-Saharan Africa, as indicated in the literature review (Oni et al., 2016;
Peltzer, 2018).
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Table 3
Independent Variables, Measurements, Types, and Tools
S/N Independent
variable

Measurement

Variable
type

Tools to use

Multimorbidity
(diabetes,
malnutrition,
cancers,
and others)

Yes/No
outcome

Categorical/
nominal

Data retrieval
form

Age

Years

Ratio

Data retrieval
form

Sex

Male/
female

Nominal/
categorical

Data retrieval
form

Marital status

Married/widow/
divorced/separated

Nominal/
categorical

Data retrieval
form

The phase of
TB treatment

Initial/continuation

Categorical/
nominal

Data retrieval
form

Initiation of
ART after
the start of
TB treatment

Before starting
TB treatment

Categorical/
nominal

Data retrieval
form

Categorical/
nominal

Data retrieval
form

After TB
treatment
Unknown

Type of TB

Pulmonary TB
(clinically
diagnosed
and bacteriogically
diagnosed)
Extrapulmonary TB
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Additional data were extracted from the ART cards of TB/HIV patients on ART.
The presence of multimorbidity was recorded as Yes, and recorded in the column labeled,
“other medications dispensed,” including nutritional supplements (Peltzer, 2018). This
data on medicines were used to come up with the most frequent chronic diseases in
TB/HIV patients, namely, diabetes mellitus, hypertension, malnutrition, pneumonia,
cancers, and others (Putnam et al., 2002). An expert physician provided the commonly
prescribed medicines in Uganda for selected chronic diseases, and this was triangulated
with the same chronic disease medical prescriptions in Uganda’s clinical guidelines. The
prescriptions from the expert and the Uganda clinical guidelines were merged and are as
indicated below:
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Table 4
Examples of some chronic diseases and their treatment
Chronic
disease
Diabetes
mellitus

Hypertension

Malnutrition

Medicines

Type of variable

Insulin, metformin,
Categorical/nominal
pioglitazone, Glipizide,
glibenclamide, Tolbutamide,
gliclazide, Acarbose,
chlorpromide
propranolol, captopril,
Categorical/nominal
nifedipine, atenolol, lisinopril,
losartan H; furosemide, methyl
dopa, Bendrofluazide,
propranolol, enalapril,
amlodipine hydralazine
Diet supplements, for example, Categorical/nominal
RUTF

Pneumonia

ceftriaxone, Levofloxacin,
Categorical/nominal
ampicillin, azithromycin,
Benzylpenicillin (xpen),
Amoxycillin, chloramphenicol,
erythromycin

Asthma

Beta agonist
Categorical/nominal
inhalers(salbutamol), steroid
inhalers, aminophylline
injections, Salbutamol,
hydrocortisone, aminophylline.
Methotrexate, actinomycin D; Categorical/nominal
cyclophosphamide,
Vincristine, Vinblastine,
Chlorambucil, Busulfan
omeprazole, lansoprazole,
Categorical/nominal
pantoprazole, cimetidine,
magnesium

Cancers

Peptic ulcer
disease

Tools to use
Data
retrieval
form

Data
retrieval
form

Data
retrieval
form
Data
retrieval
form

Data
retrieval
form

Data
retrieval
form
Data
retrieval
form

Using a letter from the MoH, permission was sought from regional referral
hospitals to access TB/HIV data from the clinics. The formal request for data use is a
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standard procedure set by the MoH to gain access to the data from health facilities in the
country. Several types of research have been conducted in regional referral hospitals. The
practice has been to usually access this data without restrictions once the letter seeking
authorization is presented. Once permission was granted, data was accessed from the Unit
TB register and ART card. The data accessed was de-identified.
The Unit TB register and ART card are the best sources of TB/HIV data. These
are the tools where patient data is recorded daily when patients are attended to TB clinics
and ART clinics. The medical health workers usually clerk, examine, investigate,
diagnose, prescribe medicines, and conduct health education. The results from the
medical processes are written in the Unit TB register and the ART card. The TB/HIV
data is cheap to collect since it can be located easily in the clinics at the regional referral
hospitals. The TB/HIV data from the ART card can also be accessed from the electronic
medical record system in the regional referral hospitals, and this is a quick and easy to
access process.
Operationalization of the Variables
This section highlights the operational definitions of both the independent and
dependent variables. The section includes how each variable was measured. The section
also includes how the scale or core was calculated. An example of how each item was
measured and calculated is illustrated.
Definitions of Independent Variables
•

Multimorbidity: Existence of more than one medical condition or situation an
individual other than TB/HIV (AMS, 2018).
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•

Age: Period from the date of birth and time of when the patient had TB/HIV
coinfection.

•

Sex: A differentiation between male and female.

•

Marital status: This is a legally defined marital state. It can be married, widowed,
divorced, separated, or none.

•

The phase of TB treatment: The phase can be the initiation phase or continuation
phase. The initiation (intensive) phase is 2 months and consists of four drugs:
rifampicin, isoniazid, pyrazinamide, and ethambutol. The initiation phase regimen
kills rapidly multiplying bacteria or semi dormant bacteria (WHO, 2014). The
continuation phase is 4 months and consists of two drugs: rifampicin and
isoniazid. The continuation phase regimen eliminates bacteria and reduces failure
and relapse (WHO, 2014).

•

The timing of initiation for ART: This is whether the patient started antiretroviral
treatment either before TB treatment or after the start of TB treatment.

•

Type of TB: TB is either extrapulmonary or pulmonary. The pulmonary TB is
either pulmonary bacteriologically confirmed (PBC) or pulmonary clinically
diagnosed (PCD).

Nature of Scales
For independent variables, the natures of scales are indicated in the paragraph
below. All the independent variables were categorical except age; they include
multimorbidity, sex, marital status, phase of TB treatment, initiation of ART before or
after the start of TB treatment, and type of TB. The following independent variables were

67
collected from the secondary data source, the Unit TB register, ART cards, patient files,
or electronic medical records. They were recorded as dichotomous variables as follows.
•

Multimorbidity: No multimorbidity = 1 and the presence of multimorbidity = 0

•

The different multimorbidities were further categorized and coded as follows: No
multimorbidity = 0; Cancer =1, Cardiovascular =2, Dermatological =3, Endocrine
=3, ENT =4, GIT =5, Hematological =6, Immunological =7, Infectious =8, Liver
=9, Lymphatic =10, Musculoskeletal =11, Neurological =12, Nutritition =13 ,
Reproductive =14, Respiratory =15, Psychological = 16

•

Age was recorded as a continuous variable 0,1, 2,3,4 --------95 years

•

Sex was recorded as a dichotomous variable male = 0 and female = 1

•

Marital status was recorded as a categorical variable, married = 0, Widowed = 1,
Divorced/separated = 2, Single = 3, Child =4

•

Phase of TB treatment, Initial phase =0, continuation = 2 and alive =3

•

Initiation of ART after the start of TB treatment Before or with TB treatment =0,
after TB treatment = 1,

•

Type of TB, Pulmonary bacteriologically confirmed (PBC) =0, Pulmonary
clinically diagnosed (PCD) =1, Extra pulmonary tuberculosis (EP TB) =2

Data Analysis Plan
SPSS Software, Data Collection, and Research Questions and Hypotheses
The statistical package for the social sciences (SPSS) for Windows Version 25
was used to analyze data. Data of the Unit TB register and electronic medical records
from the regional referral hospitals were retrieved into a data retrieval form. A copy of
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the data retrieval form and codebook are included in the appendix. The data collected in
the retrieval forms were cleaned and maintained in an excel file as codes and then
exported to SPPS; and analyzed. I checked the database for missing data, outliers, and
inconsistencies. In case of such inconsistencies, original documents were checked and
corrected. An audit log for all data changes was maintained. Priority for data cleaning and
editing was given, especially for the dependent variables, to ensure no data is missing.
Editing procedures were repeated to ensure all errors and missing variables are corrected,
and the database was declared final and locked.
Research Questions and Hypotheses
The following are research questions with corresponding null and alternative
hypotheses as written in chapter 1:
RQ1: What is the association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART?
H01: There is no association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART.
Ha1: There is an association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART
RQ2: What is the association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART?
H02: There is no association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
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Ha2: There is an association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
RQ3: What is the association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART?
H03: There is no association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
Ha3: There is an association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
RQ4: What is the association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV
patients on ART?
H04: There is no association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
Ha4: There is an association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
RQ5: What is the association between type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among
TB/HIV patients on ART?
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H05: There is no association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Ha5: There is an association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Variables, Types of Data, and Statistical Tests
The data analysis was focused on analyzing the relationship /association between
the different variables in each of the research questions. Analysis for hypothesis one was
focused on the analysis of multimorbidity as an independent variable and mortality as a
dependent variable. To ensure proper data analysis, new/dummy independent variables
were derived. All the data on multimorbidity was changed into codes. The coded data
were entered in the TB/HIV coded form (see appendix). The data was converted into
dichotomous variables, yes or no. The new variable “yes” l represented the presence, and
“no” represented the absence of multimorbidity.
All available data for the key variables is categorical except for age. For example,
the data for the independent variable of multimorbidity is yes or no. The data for the
dependent variable of mortality is also “yes” or “no.” Age is a continuous variable and
was recorded in years. The data for sex was represented as “male” or “female.” The
marital status data was coded as married, widow, separated or divorced, single or child.
The table below shows the types of variables, independent and dependent variables,
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including the statistical tests used to test each of the corresponding hypothesis/research
questions.
Table 5
Type of Variable and Statistical Tests
Research
question/
Hypothesis

Independent variable (type
of variable)

Dependent variable
(type of variable)

Statistical test

1

Presence /absence of
multimorbidity
(categorical)

mortality
(categorical)

2

Demographic
Age (ratio)
Sex (categorical)
Marital status (categorical)
Phase of TB (categorical)

mortality
(categorical)

Descriptive
analysis,
Chi-square
logistic regression
Descriptive
analysis, binary
logistic regression

mortality
(categorical)

Descriptive
analysis, binary
logistic regression

4

ART Initiation
(categorical)

mortality
(categorical)

Descriptive
analysis, binary
logistic regression

5

Type of TB (categorical)

mortality
(categorical)

Descriptive
analysis, binary
logistic regression

3

Data Analysis and Interpretation
The analysis included univariate analysis, bivariate and multivariable analysis.,
Descriptive measures like the mean, median, mode, interquartile range were used for
univariate analysis. Also, a full range for continuous data and frequencies for categorical
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data were used. The confidence intervals were set at 95%, and values were considered
statistically significant at p= < 0.05.
According to Creswell (2009), logistics regression measures the relationship
between categorical dependent variables and one or more independent variables
(Creswell,2009). To test the hypothesis, logistic regression was used to measure the
relationship between the presence or absence of multimorbidity, age, sex, marital status,
phase of TB treatment, the timing of ART initiation, and type of TB, which are
independent variables, and mortality, which is the dependent variable. The odds ratio was
used to measure the IVs and mortality as the dependent variable. The confounders were
tested for using binary logistics regression analysis.
The potential confounders (covariates) for inclusion in the study were age, sex,
and marital status (Sangha at al., 2003). Descriptive results were interpreted based on the
mean, median, frequency, and mode. In this study, the confidence interval was set at
95%, and all results were interpreted as statistically significant when P=< 0.05. For
interpretation of the outputs of logistics regression, the odds ratio was used. If the odds
ratio was higher than one, this meant multimorbidity or other IV is associated with
mortality than expected. If the odds ratio is less than one, multimorbidity or the other IVs
were less associated with mortality (Van den Akker et al., 2001).
Threats to Validity
Validity is concerned with whether the study can achieve all it is intended to
achieve through measuring. Is the observed result of the dependent variable (mortality)
associated with the independent variable’s changes (multimorbidity)? The study is likely
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to face some threats to validity, including external, internal, and construct validity. These
threats to validity were controlled to ensure the study results are correct and can be used
to the general population of TB/HIV patients on ART (Creswell, 2009). The next sections
elaborate on how external validity, internal validity, and construct validity are likely to
affect this study and how the threats to validity were minimized.
External Validity
External validity relates to whether the study findings were generalizable to the
general population. The study had external validity if the findings in the selected regional
referral hospitals could be easily related to the findings in other regional referral hospitals
(Creswell, 2009). Using a sample that is not representative of the general population
arising from, for example, selection bias is a critical threat to external validity (FrankfortNachmias & Nachmias, 2008). The attrition of the selected participants during the study
could lead to having a nonrepresentative sample. The use of secondary data with access
to a large data sample ensures that the challenge of non representative is overcome. A
sample size estimation was conducted using G Power Version 3.1.9.2 to obtain an
adequate sample size for logistic regression for a dichotomous predictor, a significant
predictor of a binary outcome (mortality), with or without other covariates. . A sample
size of 2,405 was obtained. The study has adequate power to ensure the results are
generalizable.
Internal Validity
Internal validity is the level to which a researcher can say that the independent
variable was the cause of the dependent variable. There are several threats to internal
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validity during the study that affect experimental studies, including history, maturation,
statistical regression, experimental mortality, and selection-maturation interaction. These
threats did not affect this study directly since the study is based on secondary data. Some
issues that are likely to affect this study include the missing data and missing variables.
For missing data, some statistical calculations have been developed to ensure this is not a
problem. In the case of missing variables, there was oversampling to cater for the missing
variables. Also, all the data captured was as complete as possible.
Construct Validity
According to Frankfort-Nachmias and Nachmias, construct validity is where the
instrument can measure a concept or hypothetical variable or the extent to which the
measure is theoretically sound (Frankfort-Nachmias & Nachmias, 2008). Statistical
conclusion validity refers to a situation where the sample size is too small to show any
effect (Harris, 2010). To overcome the challenge of construct validity, a literature review
was conducted on the variables to improve the conceptualization of the variables and
their impact on the measurement. The independent variables multimorbidity, age, sex,
marital status, phase of TTB treatment, the timing of ART initiation, and type of TB were
studied and their effect on the mortality dependent variable. The dependent variable for
this study is the presence or absence of multimorbidity.
Ethical Procedures
Permission was obtained from the directors of the regional referral hospitals to
access TB patient data in the Unit TB registers and, where necessary, ART cards for
patients. The records were accessed, and data abstracted. All the patient data was de-
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identified. The data will be stored for at least 5 years if any further analysis needs to be
done. In this study, patients were not interviewed, and therefore, there was no need for
using informed consent.
Regarding secondary data extraction, each participant was given a different
unique identification number recorded on the data collection tool. During data entry, the
unique identification number was used, and patient names were deleted. The data was
kept under lock and key and only be accessed to analyze it for the study purpose. The
data will be kept for at least 5 years to enable future analysis and only be accessed under
restricted circumstances.
Before collecting data, permission was sought from the IRB of Walden University
(# 01-31-20-0226229) to conduct this study. Also, permission was sought from a local
IRB Makerere University Higher Degrees Research Ethical Committee (#772). The
Uganda National Council of Science and Technology (UNCST) is mandated to approve
any research in the country. Permission was sought from the UNCST (# HS692ES) to
conduct the study in addition to the local IRB and Walden University IRB. I signed data
agreements with all the executive directors in all the nine regional referral hospitals.
Summary
This section contains a summary of the methodology that was used for this study.
The purpose of the study was to test and analyze the association between multimorbidity,
health care processes, and mortality among TB/HIV patients on ART in Uganda. The
independent variable is multimorbidity, age, sex, marital status, phase of TB treatment,
time of initiation of ART, and type of TB. The dependent variable was mortality. The
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study used a quantitative cross-sectional design and applied the review of records in nine
out of the 14 regional referral hospitals. The target population of the study was TB/HIV
patients on ART in Uganda. The sample size result was 2,405. Since the response rate
from previous studies is about 80%, the sample size to use was 2,886 patients. G Power
was used to calculate the sample size.
The statistical package for the social sciences (SPSS) for windows version 25 was
used for data analysis. The data analysis was focused on analyzing the relationship
/association between the different variables in each of the research questions. The data
analysis included descriptive and binary logistics regression. The confounders were
tested using binary logistic regression. Central tendency measures and standard deviation
were used to interpret descriptive data.
Straight forward interpretation of data was displayed using tables, graphs, and pie
charts. Inferential conclusions were drawn from data using the confidence interval set at
95% and significance level set at P =< 0.05. Any statistically significant results with data
with P <=0.05 were subjected to biological or social plausibility. Before collecting data,
permission was sought from the IRB of Walden University, a local IRB, and UNCST as
required by the country’s laws and regulations. In this study, patients were not
interviewed, and there was no need for using informed consent. The results are presented
in Chapter 4.
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Chapter 4: Results
The purpose of the study was to analyze the association between multimorbidity,
health care processes, and mortality among TB/HIV patients on ART in Uganda. I used
the health outcomes conceptual framework that allays a complex interplay between the
health system’s four domains, patient factors, care path, and health outcomes. The
independent variables were multimorbidity, age, sex, marital status, phase of TB
treatment, the timing of initiation for ART, and type of TB. The dependent variable was
mortality. I tested and analyzed the association between multimorbidity, health care
processes, and mortality among TB/HIV patients on ART. The following were the
research questions and hypotheses of the study.
Research Questions and Hypotheses
RQ1: What is the association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART?
H01: There is no association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART.
Ha1: There is an association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART
RQ2: What is the association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART?
H02: There is no association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
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Ha2: There is an association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
RQ3: What is the association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART?
H03: There is no association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
Ha3: There is an association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
RQ4: What is the association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV
patients on ART?
H04: There is no association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
Ha4: There is an association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
RQ5: What is the association between type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among
TB/HIV patients on ART?
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H05: There is no association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Ha5: There is an association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
In Chapter 4, I describe the data collection methods, the study findings in detail,
including descriptive results and results from the binary logistics regression. I provide a
summary of the research questions and a transition to Chapter 5.
Data Collection
Several institution review boards approved this study: Walden University IRB (#
01-31-20-0226229), Makerere University Higher Degrees Research Ethical Committee (
#772), and the Uganda National Council of Science and Technology (#HS692ES). The
MoH provided administrative clearance for the study, and the executive directors of the
regional referral hospitals signed data use agreements for each hospital. Also, the
research committees of three hospitals provided additional ethical approval. All these
documents were presented to the respective hospital authorities at the time of data
abstraction.
The experienced health workers in different hospitals abstracted data from Unit
TB registers, ART cards, and patients’ files onto a data abstraction tool starting in August
2020, and abstraction was completed on November 20, 2020. The data included a
hospital’s name, year, unique ID, age, sex, marital status, DR TB status, type of TB, TB
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treatment outcome, ART number, other medications, and other diseases diagnosed other
than TB or HIV. The abstraction tool did not include direct identifiers, and patient names
were not included in the data set. There were no discrepancies in the data collection plan.
WHO (2020) estimated about 35,000 people living with HIV fell ill with TB in Uganda
in 2019, with 25,125 notified to WHO, and 25,125 were on ART.
I used G Power Version 3.1.9.2 to determine the minimum sample size for logistic
regression for a dichotomous predictor. The following information, including statistical
power, alpha, and effect size, was used in calculating sample size. The statistical power
of 80% (0.8) was used to test a relationship between the independent and dependent
variables. For alpha, I used a predetermined figure of 0.05 to maintain the high power of
the study. Pr (Y = 1 | X = 1) H1, and I assumed the probability of mortality for TB/HIV
patients on ART with multimorbidity was H1 = 0.18. Then Pr (Y = 1 | X = 1) H0 = the
probability of mortality (Y = 1) when someone has no multimorbidities. If the probability
of mortality for patients without multimorbidity is H0 = 0.09 (TB patients without HIV),
the two probabilities give an odds ratio of 2.524. Then R squared (R2 other X) = the
expected squared multiple correlation coefficient (R squared) between the main
categorical predictor (multimorbidity status) and all other covariates. R squared
represents the amount of variability in the main predictor (multimorbidity) that is
accounted for by the covariates. X param π = The proportion of multimorbidity cases and
are dead; this was estimated at 0.5. The calculated sample size was 2,405. The sample
size was adjusted to 2,886 to compensate for the 20% missing variables. However, during
data abstraction, all data on all eligible TB/HIV patients on ART were abstracted from
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the 9 regional referral hospitals, making 3,580 records. The 3,580 records were adequate
to answer the research questions. The data were used to make conclusions about the
mortality, multimorbidity, and health care processes among TB/HIV patients on ART in
Uganda.
Results
The representative sample of the study was 2,880 TB/HIV patients on ART in
Uganda. As shown in Table 6, 3,580 TB/HIV patients on ART in Uganda were abstracted
from the nine hospitals. The majority of the TB/HIV patients (95%; 3,402) had
susceptible TB; only 5% (178) had DR–TB. One hospital had the majority of patients at
763, while the last had the least patients at 151. A total of 749 (20.9%) of TB/HIV
patients were dead, while 1016 (28.4%) had at least one multimorbidity, and 344 (30%)
of those who were dead had multimorbidity. The top five most common multimorbidities
were gastrointestinal, nutritional, respiratory, neurological, and infectious diseases (see
Table 7).
Table 6
Regional Referral Hospital Statistics
Regional referral hospital
Regional Referral hospital A
Regional Referral hospital B
Regional Referral hospital C
Regional Referral hospital D
Regional Referral hospital E
Regional Referral hospital F
Regional Referral hospital G
Regional Referral hospital H
Regional Referral hospital I

Code
0
1
2
3
4
5
6
7
8
Total

Frequency

Percent

763
426
490
408
388
316
405
151
233
3,580

21.3
11.9
13.7
11.4
10.8
8.8
11.3
4.2
6.5
100.0
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Table 7
Multimorbidities in TB/HIV Patients on ART

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Disease category
GIT
Nutrition
Respiratory
Neurological
Infectious
Musculoskeletal
Cardiovascular
Renal
Hematological
Dermatological
Endocrine
Reproductive
Immunological
Otorhinolaryngology
Cancer
Liver
Psychological
Lymphatic
Total

Frequency
275
127
119
101
74
44
42
36
33
30
23
23
22
18
17
16
10
6
1016

%
27.1
12.5
11.7
9.9
7.3
4.3
4.1
3.5
3.2
3.0
2.3
2.3
2.2
1.8
1.7
1.6
1.0
0.6

The study had one dependent variable, mortality, and seven independent
variables: (a) sex, (b) age, (c) marital status, (d) type of TB, (e) ART initiation, (f) TB
treatment phase, and (g) multimorbidity clusters. All variables were categorical except
age. Age was measured in years and was the only independent continuous variable. The
minimum age was 0.42 years; the maximum age was 95 years; the mean age was 36.3
years, the median age was 36 years, and the mode age was 30 years. Table 8 shows the
details of the dependent and independent categorical variables. The total sample size was
3,580 for each variable except age and marital status with 3,579 and 3,245, respectively.
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All variables met the criteria for evaluation of statistical assumptions for binary logistics
regression.
Table 8
Descriptive Statistics for Categorical Variables
N
Statistic
3580

Type of
variable
Dependent

Sex

3580

Independent

Marital
status

3,245

Independent

Type of TB:

3580

Independent

ART Initiation

3580

Independent

Phase of
TB treatment

3500

Independent

Multimorbidity
clusters

3580

Independent

Mortality

Categories

Code

Alive
Dead
Male
Female
Married
Widowed
Divorced/Separated
Single
Child
Missing system
PBC
PCD
EPTB
Before TB treatment
after TB treatment
Initial phase
Continuation phase
NA
Missing system
MM0
MM1
MM2ormore

0
1
0
1
0
1
2
3
4
0
1
2
0
1
0
1
3
0
1
2

Frequency
Statistic
%
2831
79.1
749
20.9
2087
58.3
1493
41.7
1646
46.0
210
5.9
667
18.6
507
14.2
215
6.0
335
9.4
1452
40.6
1870
52.2
258
7.2
2907
81.2
673
18.8
564
15.8
105
2.9
2831
79.1
80
2.2
2564
71.6
824
23.0
192
5.4

Evaluating Statistical Assumptions
I used binary logistic regression to analyze the data set on TB/HIV patients on
ART in Uganda. As a recommendation, the data should meet all the seven assumptions of
binary logistics regression before applying the analysis (Laerd, 2017). The first four
assumptions are concerned with the study’s design, while the other three assumptions are
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concerned with the nature of data (Laerd, 2017). The requirement is for the data to meet
all seven assumptions before analyzing using binary logistics regression.
The study met the assumption1. The first assumption requires that a dichotomous
dependent variable (DV). The DV for this study is mortality, and it is dichotomous, with
mortality coded as one and no mortality coded as zero. Assumption 2 was met.
Assumption 2 required that the independent variables (IV) should either be continuous or
categorical. This study had seven IVs, one of which was continuous, age measured in
years. The rest of the six IVs are categorical multimorbidity clusters, sex, marital status,
time of ART initiation, phase of TB treatment, and type of TB. The study met assumption
3. Assumption 3 required independent observations and mutually exclusive and
exhaustive variables. Each observation captured in its row, and the observations have no
relationship between each and mutually exclusive. All seven variables met this
assumption. The study met the assumption 4 for only six out of the seven IVs.
Assumption 4 required that each of the independent variables have at least 15 cases
(Laerd, 2017). All the independent variables in this study have more than 15 cases each
except phase of TB treatment. The static count was 3580 for sex, time of art initiation,
phase of TB treatment and type of TB, and multimorbidity clusters, while marital status
was 3,245 and age was 3,579. The phase of TB treatment IV had zero cases in the binary
outcome, as shown in Table 9. To address this, I answered RQ3 using descriptive
statistics.
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Table 9
The Phase of TB Treatment With Fewer Than 15 Cases in the Binary Outcome
Code Initial Continuation
No mortality 0
0
0
Mortality
1
564
105
Total
564
105

Completion
2831
0
2831

Total
2831
669
3500

Assumption 5 was met. Assumption 5 assumed that there should be a linear
relationship between the independent continuous variables and the logit transformation of
the categorical dependent variable (Box & Tidwell, 1962). I tested this assumption using
the Box Tidwell approach. The only continuous independent variable in this study is age.
I conducted a Box Tidwell procedure to assess the linearity of age (continuous variable)
against the logit transformation of mortality as a dependent variable (Box & Tidwell,
1962). The assessment showed that ln -age was not significant (p> 0.05), meaning there
is a linear correlation between age and the logit transformation of mortality (Laerd,
2017). Assumption 6 related to multicollinearity was not tested since it is only tested
when there are many independent study variables. This study had only bivariate
independent variables without multivariate independent variables. The study satisfied
Assumption 6.
The study satisfied Assumption 7 that there no significant outliers. I tested this
using case wise diagnostics and analyzed each IV against the dependent variable
mortality. The output did not produce a case wise plot since it had no outliers for the
independent variables.
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Statistical Analysis by Research Question
This section details the statistical analysis of each research question. The
following is research question one, the null and alternate hypothesis.
RQ1: What is the association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART?
H01: There is no association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART.
Ha1: There is an association between multimorbidity (disease clusters) and
mortality among TB/HIV patients on ART
I conducted a binomial logistic regression to test an association between
multimorbidity (disease clusters) and mortality among TB/HIV patients on ART in
Uganda. The outcome variable was mortality, while the independent variable was
multimorbidity. The IV had three levels: (1) no multimorbidity, (2) one multimorbidity,
and (3) two or more multimorbidities. Mortality was classified as 1 for dead and 0 for
alive. The logistics regression model was also significant with χ2 (2) = 37.167, p<0.0001.
The model explained 1.6% (Nagelkerke) of the variance in mortality and correctly
classified 79.1% of the mortality cases.
Table 10 shows that the two levels of the independent variables in the model were
statistically significant. The two levels of the independent variables were one
multimorbidity cluster and two or more multimorbidity clusters. The TB/HIV patients on
ART with one multimorbidity were 1.658 times more likely to die (P<0.0001 for each at
95% CI (1.388 – 1.992) compared to patients with no multimorbidity. The TB/HIV
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patients on ART with two or more multimorbidities were 1.901 times more likely to die
(p<0001, 95% CI (1.373 -2.633) compared to TB/HIV patients on ART with no
multimorbidity.
Table 10
Logistics Regression Predicting the Likelihood of Mortality Based on Multimorbidity
Clusters in TB/HIIV Patients on ART in Uganda
B

S.E.

Wald

df

Sig.

Exp(B)

95% C.I. for
EXP(B)
Lower Upper

No multimorbidity
38.217 2 .000
(MM0)
One multimorbidity
.506
.094 29.209 1 .000 1.658
1.380
cluster (MM1)
Two or more
.642
.166 14.943 1 .000 1.901
1.373
multimorbidity
cluster (MM2+)
Constant
–1.497 .051 859.066 1 .000
.224
Note. The reference variable multimorbidity clusters is no multimorbidity.

1.992
2.633

RQ2: what the association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART?
H02: There is no association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
Ha2: There is an association between demographic factors (sex, age, and marital
status) and mortality among TB/HIV patients on ART.
The second research question was answered using a binomial logistic regression
to test for an association between demographic factors (sex, age, and marital status) and
mortality among TB/HIV patients on ART in Uganda. The outcome variable was
mortality, while the independent variables were sex, age, and marital status. Sex coded as
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male 0 female 1, Age is a continuous variable measure in years, while marital status was
coded as married 0, widowed 1, separated/divorced 2, single 3, and child 4. Mortality is
classified as 0 for dead and 1 for alive 0. The logistics regression model was significant
with χ2 (6) = 10.339, p>0.001 (0.001). The model explained 0.11% (Nagelkerke) of the
variance in mortality and correctly classified 80.5% of the mortality cases.
Table 11 shows that the two predictor variables in the model, separated or
divorced, and single were statistically significant. The TB/HIV patients on ART that were
separated or divorced were 1.591 times more likely to die (P<0.0001) (0.000); (95% CI:
1.279 -1.98)1 as compared to married patients. The TB/HIV patients on ART that were
single were 1.381 times more likely to die (P<0.0001) (0.000); ( 95% CI: 1.069 -1.782)
as compared to married patients.
Table 11
Logistics Regression Predicting the Likelihood of Mortality Based on Sex, Marital Status,
and Age

Sex: M = 0, F = 1 (1)
Marital status
Married
Widowed
Divorced/separated
Single
Child
Age
Constant

B

S.E.

Wald

df

Sig.

Exp(B)

–.031

.092

.117

1

.732

.969

–.110
.465
.322
.053
–.002
–1.492

.215
.112
.130
.227
.004
.189

22.006
.263
17.309
6.106
.055
.166
62.562

4
1
1
1
1
1
1

.000
.608
.000
.013
.815
.684
.000

.896
1.591
1.380
1.055
.998
.225

95% C.I. for EXP(B)
Lower
Upper
.809
1.160

.588
1.279
1.069
.676
.990

1.364
1.981
1.782
1.645
1.007

Note. The reference variable for sex is male and for marital status is married.
RQ3: What is the association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART?
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H03: There is no association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
Ha3: There is an association between the phase of TB treatment (initiation and
continuation) and mortality among TB/HIV patients on ART.
This question violated the third assumption, which states that each independent
variable should have more than 15 cases (Laerd, 2017). Three variables had zero alive
cases for the initial continuation and zero dead cases for completion. The results shown in
Table 12 are descriptive statistics of TB/HIV patients n the different phases of TB
treatment.
Table 12
The Phase of TB Treatment With Less Than 15 Cases in the Binary Outcome
Initial phase
Continuation
Completed treatment
Missing system
Total

Code
0
1
3
-

Frequency
564
105
2831
80
3500

Percent
15.8
2.9
79.1
2.2
97.8

RQ4: What is the association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV
patients on ART?
H04: There is no association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
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Ha4: There is an association between the time of initiation of ART (before the
start of TB treatment and after the start of TB treatment) and mortality among
TB/HIV patients on ART.
For research question four, a binomial logistic regression was conducted to test
for an association between the time of initiation of ART (before the start of TB treatment
and after the start of TB treatment) and mortality among TB/HIV patients on ART. The
outcome variable was mortality, while the independent variable was the time of initiation
of ART. The time of initiation of ART was categorized as before the start of TB
treatment coded as 0 and after the start of TB treatment coded as 1. Mortality was
classified as 1 for dead and 0 for alive. The logistics regression model was also
significant with χ2 (1) = 31.011(P = 0.000), p<0.001. The model explained 1.3%
(Nagelkerke) of the variance in mortality and correctly classified 79.1% of the mortality
cases.
Table 13 shows that the predictor variables in the model, time of initiation of
ART, was statistically significantly associated with mortality of TB/HIV patients on
ART. The TB/HIV patients on ART who began ART treatment after TB treatment were
1.899 times more likely to die (P<0.0001); ( 95% CI: 1.496 -2.410) than patients who
started ART before TB treatment.
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Table 13
Logistics Regression Predicting the Likelihood of Mortality Based on ART Initiation in
TB/HIV Patients
B

S.E.

Wald

df

Sig.

Exp(B)

95% C.I. for
EXP(B)
Lower Upper
1.496
2.410

Time of
.641
.122
27.810 1 .000 1.899
initiation of
ART
Constant
–1.868
.113
272.161 1 .000
.154
Note. The reference variable for the time of initiation on ART is initiation after TB
treatment.

RQ5: What is the association between type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among
TB/HIV patients on ART?
H05: There is no association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
Ha5: There is an association between the type of TB (pulmonary bacteriologically
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality
among TB/HIV patients on ART.
To answer the fifth research question, I conducted a binomial logistic regression
to test an association between Type of TB and mortality among TB/HIV patients on
ART. The outcome variable was mortality, while the independent variable Type of TB.
The variable type of TB was coded into three, pulmonary bacteriologically confirmed
(PBC) = 0, pulmonary clinically diagnosed (PCD) =1 and extrapulmonary (EPTB) =2.
The logistics regression model was also significant with χ2 (2) = 41.486, p<0.001. The
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model explained 1.4% (Nagelkerke) of the variance in mortality and correctly classified
79.1% of the mortality cases.
Table 14 shows that the two predictor variables in the model, PCD, and EP TB,
were statistically significant. The TB/HIV patients on ART with PCD were 1.275 times
more likely to die (P<0.0001 for each; 95% CI: 1.072 -1.518) than patients with PBC.
The TB/HIV patients on ART with EP TB were 2.355.087 times more likely to die
(P<0.0001 for each; 95% CI: 1.760 – 3.150) than patients with PBC.
Table 14
Logistics Regression Predicting the Likelihood of Mortality Based on the Type of TB
Treatment for TB/HIV Patients on ART
Category

B

S.E.

Wald

df

Sig.

Pulmonary
33.778 2 .000
bacteriologically
positive (PBC)
Pulmonary
.243
.089 7.516
1 .006
clinically
diagnosed (PCD)
Extrapulmonary
.856
.149 33.249 1 .000
(EP)
Constant
–1.532 .069 498.006 1 .000
Note. The reference for the type of TB variable was PCD.

Exp(B)

95% C.I. for
EXP(B)
Lower
Upper

1.275

1.072

1.518

2.355

1.760

3.150

.216

Summary
This study used cross sectional data from nine out of 14 regional referral
hospitals. The nine hospitals were systematically selected. The data were extracted from
all TB/HIV patients on ART registered in 2017, 2018, and 2019 from the Unit TB
registers and ART cards or ART electronic medical records. The final records collected
and cleaned were 3,580 records. The study showed significant results for all objectives
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except objective 3. The study showed that TB/HIV patients on ART, with one
multimorbidity and two or more multimorbidities, were 1.658 and 1.901 times more
likely to die than patients with no multimorbidity. The TB/HIV patients on ART that
were separated or divorced and single were 1.591 and 1.381 times, respectively, more
likely to die than married patients. Age and sex were not significantly associated with
mortality. The TB/HIV patients on ART who began ART treatment after TB treatment
were 1.899 times more likely to die than patients who started ART before TB treatment.
The TB/HIV patients on ART with PCD and EPTB were 1.275and 2.087 times,
respectively, more likely to die than patients with PBC. In chapter 5, I interpreted the
results of the findings, highlight the limitations, significance, and made recommendations
for future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of the study was to analyze the association between multimorbidity,
health care processes, and mortality among TB/HIV patients on ART in Uganda. The
independent variables were multimorbidity, age, sex, marital status, type of TB, phase of
TB treatment, and timing of initiation for ART. The dependent variable was mortality.
This study was designed to use quantitative research methods with a cross-sectional
design, coupled with a retrospective review of medical records from the Unit TB register,
ART cards, patient files, and electronic medical records.
The data were cross sectional from nine out of 14 regional referral hospitals. The
nine hospitals were systematically selected. The data were from all TB/HIV patients on
ART registered in 2017, 2018, and 2019, in the Unit TB registers and ART cards, patient
files, or ART electronic medical records. The total of final records collected and cleaned
were 3,580. The study showed significant results for all objectives except Objective 3.
TB/HIV patients on ART with one multimorbidity, two or more multimorbidities,
separated or divorced, and single were associated with mortality. Age and sex were not
significantly associated with mortality. TB/HIV patients on ART who began ART
treatment after TB treatment were more likely to die than patients who started ART
before TB treatment. TB/HIV patients on ART with PCD were more likely to die than
patients with PBC. TB/HIV patients on ART with EPTB were more likely to die than
patients with PBC. In Chapter 5, I interpreted the results, highlighted the limitations,
implications of the study, made future research recommendations, and concluded the
study.

95
Interpretation of Findings
In general, multimorbidity increases premature death risk (AMS, 2018). Studies
in high-income and middle-income countries have shown that the higher the number of
multimorbidities, the higher the chances of death (Lix et al., 2016; Nunes et al., 2016;
Willadsen et al., 2018). There is little literature about multimorbidity and its association
with mortality among TB/HIV patients on ART (Mchunu et al., 2016; Musaazi et al.,
2019; Stijnberg et al., 2019; Tola et al., 2019). In TB/HIV patients, multimorbidity has
been postulated to lead to death. However, findings have not always been definitively
backed by inferential statistics (Mchunu et al., 2016; Musaazi et al., 2019; Stijnberg et al.,
2019; Tola et al., 2019).
In my study, the results showed that TB/HIV patients on ART with one
multimorbidity were 1.658 times more likely to die than patients with no multimorbidity.
The TB/HIV patients on ART with two or more multimorbidities were 1.901 times more
likely to die than patients with no multimorbidity. The results are aligned to the general
literature from high-income countries that show that the higher the number of
multimorbidities, the higher the chances of death (Lix et al., 2016; Nunes et al., 2016;
Willadsen et al., 2018). However, studies conducted in Africa have concentrated on
prevalence and multimorbidity patterns rather than their association with mortality (Oni
et al., 2016; Peltzer et al., 2018). The results of this study add new knowledge to the
existing body of literature for TB/HIV patients on ART, showing that an increase in
multimorbidity is associated with mortality. The top 10 multimorbidity clusters included
gastrointestinal disease, nutritional, respiratory, neurological, infections, musculoskeletal,
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renal, cardiovascular, hematological, and dermatological diseases. There is a need to
reexamine current practices, including integrated TB/HIV patient care models and care
for people with advanced HIV/AIDS disease (WHO, 2017). Stakeholders need to
improve the screening, diagnostic, and management algorithms to address multimorbidity
in TB/HIV patients.
Generally, researchers of marital status have consistently shown that unmarried
people have poorer health outcomes than married people do (Hilz & Wagner, 2018;
Kaplan & Kronick, 2006). In this study, the mortality of unmarried individuals, except
for the widowed, was more likely to happen as compared to married people. The
unmarried people included those who were divorced, separated, and single. However, the
widowed population’s mortality compared to the married population was not significant.
Based on previous research, unmarried people tend to have issues with income, physical
activity, and social networks, which may predispose them to high mortality (Hilz &
Wagner, 2018). Several studies have shown that married people use health services more
than people who are not married (Rutaremwa & Kabagenyi, 2016). In Uganda, widowed
people could be excluded from this group because they usually have income left by their
deceased spouse (Rutaremwa & Kabagenyi, 2016). There is a need to pay attention to the
separated and single if mortality among TB/HIV patients is averted.
Age and sex were not associated with mortality among TB/HIV patients on ART
in this study. This finding departs from earlier findings on studies that reflect that sex and
age are associated with mortality in TB/HIV patients (Englebrecht et al., 2017; Haregu et
al., 2012). However, some studies have shown no association between mortality, gender,
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and age (Lisboa, 2019; Tabarsi et al., 2012). Increasing age is generally associated with
mortality in developed countries, while some studies in Africa indicate that young age is
associated with mortality among TB/HIV patients on ART (Englebrecht et al., 2017; Oni
et al., 2015). Generally, being female is associated with death in developed countries,
whereas being male is associated with death in TB/HIV patients in Africa (Hood et al.,
2019; Teklu et al., 2017).
In this study, I also included a variable for the phase of TB treatment (initiation
and continuation) in testing for mortality among TB/HIV patients on ART. The majority
of patients completed treatment (79.1%). Among TB/HIV patients on ART who did not
complete treatment, 15.8% died in the initial phase and 2.9% died in the continuation
phase. These findings are similar to results in other studies in which more TB/HIV
patients died in the initial phase of TB treatment than in the continuation phase (Hood et
al., 2019; Musaazi et al., 2019; Stijnberg et al., 2019). Delay in diagnosis, delay in
initiation of TB and ART, and IRIS could contribute to mortality (Stijnberg et al., 2019;
Tola et al., 2019). The results reconfirm that the majority of patients die in the initial
phase than in the continuation phase. However, it is not clear whether the initial phase or
continuation phase is statistically associated with mortality.
Many researchers have found that ART is protective among TB/HIV patients
(Musaazi et al., 2019; Nagu et al., 2017; Torrens et al., 2016). In this study, the TB/HIV
patients on ART who began ART treatment after TB treatment were 1.899 times more
likely to die than patients who started ART before TB treatment. This finding is similar to
findings in other studies and implies that the earlier the ART begins, the more protective
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it will be to patients (Musaazi et al., 2019; Nagu et al., 2017; Torrens et al., 2016). Delay
in the initiation of ART is associated with high mortality, and ART initiation improves
clinical outcomes (Ford et al., 2018). However, the reasons for high mortality among
TB/HIV patients on ART need to be explored at the clinical intervention level.
TB/HIV patients on ART with PCD or EPTB in this study were more likely to die
than patients with PBC. In this study, I found that TB/HIV patients on ART with PCD or
EPTB were 1.275 and 2.087 times, respectively, more likely to die than patients with
PBC. The results are similar to results from researchers in Uganda and Ethiopia who
found that patients with PCD and EPTB were more likely to die than patients with PBCs
(Biruk et al., 2016; Lisboa et al., 2019; Musaazi et al., 2019; Tola et al., 2019). The
higher mortality among PCD and EPTB than PBC may be due to delay in diagnosing
PCD and EPTB, which may take more than a month (Lisboa et al., 2019).
In this study, I used the health outcomes model with four domains: characteristics
of the health care system, patient characteristics, health care path, and patients
outcomes(Canadian Institute for Health Information, 2008). The health outcomes
conceptual framework was used because of its simplicity in studying patient-level
outcomes. The independent variables were part of only two domains of the study, patient
characteristics (sex, age, marital status, multimorbidity) and health care path (timing of
ART and phase of TB treatment) that were direct predictors of patient outcomes
(mortality). However, patient characteristics (sex, age, marital status, and multimorbidity)
were also indirect predictors of patient outcomes (Sbagiria et al., 2016).
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The study results are in line with the health outcomes conceptual framework. The
independent variables—patient characteristics (marital status, multimorbidity) and health
care path (timing of ART and phase of TB treatment)—were direct predictors of
mortality as reflected in the statistically significant results. In this study, age and sex were
not statistically significant and therefore not predictors of mortality. Age and sex could
have been indirect predictors of mortality; however, this prediction was not proven in this
study. The health outcomes model is used in public health to predict and improve patient
outcomes. The conceptual framework is also used as a TB/HIV framework to monitor
and evaluate TB/HIV activities (WHO, 2015). The framework has also been used in
health outcomes research, primarily for the Hepatitis C virus (Sbagiria et al., 2016).
Limitations of the Study
In this study, the health outcomes conceptual framework was used that has four
domains. However, only three domains were used to study patient characteristics, health
care path, and patient outcomes. The health systems care domain was not studied. In
addition, a few factors from the three domains were studied as represented by the
independent variables (multimorbidity, age, sex, marital status, type of TB, phase of TB
treatment, and timing of initiation for ART) and dependent variable (mortality). Despite
this limitation, the study brought out new findings on the association of multimorbidities
and mortality. The study has also shown consistent results with other studies (Musaazi et
al., 2019; Nagu et al., 2017; Torrens et al., 2016;). The need for future studies to be
designed to include more factors that are missing in this study is conspicuous.
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This study used routine data from Unit TB registers, ART cards, HIV patient files,
and electronic medical records. Secondary routine data usually have missing records.
Patients who had incomplete data on the outcome variable were left out, especially for
patients registered at the regional referral hospital for TB care but receiving ART at
peripheral health facilities. Also, patients with other unfavorable outcomes like the loss to
follow-up and non evaluated were left out since the outcome variable was binary with
dead or alive. However, all independent variables were captured, including marital status
and age, which had missing data. Another limitation could be about diagnostic errors.
The diagnostic tests depended on the equipment used to make the diagnostic tests during
routine care. The accurate and correct records depended on the clinician. To minimize
this error, the health workers abstracted data from primary data tools filled by the
clinician during service delivery.
Although these limitations exist, this study’s strength was using the large sample
size of 3,580 patients and systematic sampling from nine out of 14 patients. The large
sample size and systematic sampling improved the internal and external validity of the
study. The study design was appropriate for the research questions to highlight the
significant findings related to death among TB/HIV on ART. The study findings can be
generalized to TB/HIV patients on ART with associated mortality in Uganda and similar
settings.
Recommendations
Mortality for TB/HIV patients on ART is an outcome with some known
confounders that were not part of the TB and ART tools. These included socioeconomic
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characteristics and behavioral factors (Tola et al., 2019). The socioeconomic factors left
out include income, social support, and education status. The behavioral factors left out
were alcohol consumption and cigarette smoking. These variables would have further
supported the explanation of mortality on TB/HIV patients on ART. In the future,
prospective studies collecting primary data should include all the relevant variables on all
socioeconomic factors (income, social support, education status) and behavioral factors
(alcohol consumption, cigarette smoking).
I did not include some treatment and disease related factors like adherence of
patients on ART and TB treatment, CD4 cell testing, and viral load. There is a need for
future research to check for an association between patient adherence to ART and TB
treatment, CD4 cell testing, viral load, and mortality in TB/HIV patients on ART. The
results would inform HIV and TB programs on interventions to protect TB/HIV patients
from death and interventions to protect HIV patients on ART from developing advanced
HIV disease. A prospective rather than a retrospective research study could be conducted
with a clear intention to follow up the well-documented multimorbidities among TB/HIV
patients on ART.
In this study, I did not cover individual multimorbidities. Multimorbidity was
studied as disease clusters. There is a need to understand further the individual diseases
and how they are associated with mortality in TB/HIV patients on ART. Such a study
would provide vital information on how patient-family-centered care can be delivered to
improve mortality among TB/HIV patients on ART in Uganda.
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Implications
Health stakeholders can use the significant findings that arise from the study to
influence positive social change with an impact on the lives of patients, families, and
communities. This study showed significant findings that several multifaceted factors are
associated with mortality among TB/HIV patients on ART in Uganda. The policymakers,
managers in governments, and NGOs should advocate for change in policy, practice, and
research at different levels, including networks of TB patients coinfected with TB. This
study has developed new knowledge; there is an association between multimorbidity
(disease clusters) and mortality among TB/HIV patients on ART. All patients with
multimorbidity need appropriate care to avoid mortality. In previous studies, patient–
family-centered care was beneficial to patients with multimorbidity (Boyd & Fortin,
2010). The dually infected TB/HIV patients on ART that have multimorbidity will need
patient-family-centered care. The health managers need to advocate for patient – familycentered care at all healthcare levels, including the patient, family, and healthcare teams
(Boyd& Fortin, 2010).
Furthermore, the study showed that mortality in TB/HIV patients on ART was
associated with those who were separated or divorced and single (Robards et al., 2012).
The health workers managing patients have to think about the families and making sure
those who are either separated, divorced, and single are given appropriate nonclinical
care at the TB/HIV clinics. Also, the TB/HIV patients on ART who began ART treatment
after TB treatment were 1.899 times more likely to die than patients who started ART
before TB treatment. Care providers should prioritize and closely monitor all patients
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who start ART late for care at the health facilities to make sure they do not die. The
TB/HIV patients on ART with PCD and EPTB were 1.275 and 2.087 times, respectively,
more likely to die than patients with PBC. Extra care has to be taken by health care
workers to screen for PCD and EPTB in TB/HIV patients on ART in patient-familycentered care. Also, community TB/HIV services have to target patients with
multimorbidity, separated/ divorced or single, with PCD or EPTB, and those who start
ART after TB treatment.
The TB and HIV programs should implement patient-family-centered care at the
health facility and community levels in line with universal health coverage principles
described by WHO under the sustainable development goals. The TB and HIV programs
should screen and treat all TB/HIV patients with advanced HIV disease who have other
diseases, including GIT, nutritional, respiratory, neurological, and infections,
musculoskeletal, renal, cardiovascular. The two programs should endeavor to identify
patients who are single, separated, or divorced, with EPTB or PCD, who started ART
after TB treatment and ensure they get appropriate care. Finally, sexual contacts of
people with HIV may have HIV and TB. The HIV programs should screen for HIV
among all sexual contacts of TB/HV patients, which helps identify new HIV patients
early and start treatment before they get TB. Screening household contacts of all TB/HIV
patients for TB is already a practice that should continue.
Conclusions
This study contributed to new knowledge, confirmed the findings from previous
studies, and presented findings that differed from the findings of other studies about
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multimorbidity, health care processes, and mortality among TB/HIV patients on ART.
The new knowledge: TB/HIV patients on ART with one or more multimorbidities were
more likely to die than patients with no multimorbidity. Based on the existing literature,
no TB/HIV study brought out this critical finding. The policymakers and practitioners
should use this new knowledge to guide the management of multimorbidities among
TB/HIV patients on ART to prevent premature deaths.
The study has also confirmed the findings from previous studies. The TB/HIV
patients on ART that were separated/divorced or single were 1.591 and 1.381 times,
respectively, more likely to die than married patients. This finding is similar to
knowledge generated from other general studies and studies on TB and TB/HIV. Looking
out for unmarried people to minimize mortality among TB/HIV patients on ART is a
priority. More to this finding, TB/HIV patients on ART who began ART treatment after
TB treatment were 1.899 times more likely to die than patients who started ART before
TB. ART has always been protective in HIV and TB/HIV patients, especially when it
started early (Musaazi et al., 2019). The practitioners should endeavor to start ART as
soon as possible in TB/HIV patients (WHO, 2017).
The study has also presented findings that differed from the findings of other
studies. Age and sex were not significantly associated with mortality, unlike in other
studies, where mortality was associated with age and sex. All these findings highlight the
need for implementation of patient-family-centered care at the health facility and
community levels. More studies are needed to understand further the individual
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multimorbidities associated with mortality and how patient-family-centered care can be
delivered to improve mortality among TB/HIV patients on ART in Uganda.
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